

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

The UroLife study: A prospective cohort on dietary and lifestyle habits in relation to non-muscle-invasive bladder cancer prognosis and health-related quality of life

Journal:	BMJ Open
Manuscript ID	bmjopen-2019-030396
Article Type:	Protocol
Date Submitted by the Author:	12-Mar-2019
Complete List of Authors:	de Goeij, Liesbeth; Radboudumc, Department for Health Evidence Westhoff, Ellen; Radboudumc, Department for Health Evidence Witjes, JA; Radboudumc, Department of Urology Aben, Katja; Netherlands Comprehensive Cancer Organisation; Radboudumc, Department for Health Evidence Kampman, Ellen; Wageningen University Kiemeney, B; Radboudumc, Department for Health Evidence Vrieling, Alina ; Radboudumc, Department for Health Evidence
Keywords:	Urological tumours < ONCOLOGY, EPIDEMIOLOGY, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT



1 2		
2 3 4	1	The UroLife study: A prospective cohort on dietary and lifestyle habits in relation to
5 6	2	non-muscle-invasive bladder cancer prognosis and health-related quality of life
7 8	3	
9 10	4	Liesbeth de Goeij ^a , Ellen Westhoff ^a , Alfred J. Witjes ^b , Katja K.H. Aben ^{a,c} , Ellen Kampman ^d ,
11 12	5	Lambertus A.L.M. Kiemeney ^{a,b} , Alina Vrieling ^{a*}
13 14	6	
15 16 17	7	^a Radboud university medical center, Radboud Institute for Health Sciences, Nijmegen, The
18 19	8	Netherlands
20 21 22	9	^b Radboud University Nijmegen Medical Center, Department of Urology, Nijmegen, The
23 24 25	10	Netherlands
26 27	11	° Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands
28 29 30	12	^d Wageningen University, Division of Human Nutrition and Health, Wageningen, The
31 32	13	Netherlands
33 34 35	14	
36 37	15	*Corresponding author: Dr. Alina Vrieling, Radboud university medical center, Department
38 39 40	16	for Health Evidence (Mailbox 133), P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.
40 41 42	17	Tel: +31 24 3616944, Fax: +31 24 3613505, e-mail: Alina.Vrieling@radboudumc.nl
43 44 45	18	
46 47	19	Word count: 2973
48 49 50 51 52 53 54 55 56 57 58 59 60	20	

ABSTRACT

Introduction:

Patients with non-muscle-invasive bladder cancer (NMIBC) have a good survival but are at high risk for tumour recurrence and disease progression. It is important to identify lifestyle habits that may reduce the risk of recurrence and progression and improve health-related quality of life (HRQOL). This paper describes the rationale and design of the UroLife study. The main aim of this study is to evaluate whether dietary and other lifestyle habits are related to prognosis and HRQOL in patients with NMIBC.

Methods and analysis:

The UroLife study is a multi-centre prospective cohort study among more than 1,100 newly diagnosed patients with NMIBC recruited from 22 hospitals in the Netherlands. At six weeks and three, 15, and 51 months after diagnosis, participants fill out a general questionnaire, and questionnaires about their dietary habits, lifestyle, and HRQOL. At three, 15, and 51 months after diagnosis, information about fluid intake and micturition is collected with a four-day diary. At three and 15 months after diagnosis, patients donate blood samples for DNA extraction and (dietary) biomarker analysis. Tumour samples are collected from all patients with T1 disease to assess molecular subtypes. Information about disease characteristics and therapy for the primary tumour and subsequent recurrences is collected from the medical records by the Netherlands Cancer Registry.

Ethics and dissemination:

The study protocol has been approved by the Committee for Human Research region Arnhem-Nijmegen (CMO 2013-494). Patients who agree to participate in the study provide written informed consent. The findings from our study will be disseminated through peer-reviewed scientific journals and presentations at (inter)national scientific meetings. Patients will be informed about the progress and results of this study through biannual newsletters and through the website of the study and of the bladder cancer patient association.

1 2		
2 3 4	48	Keywords: bladder cancer, diet, lifestyle, biomarkers, recurrence, prognosis, quality of life,
5 6 7	49	cohort, study protocol
8 9	50	
10 11 12	51	STRENGTHS AND LIMITATIONS OF THIS STUDY
12 13 14	52	Large multicenter prospective cohort study of NMIBC patients recruited shortly after
15 16	53	diagnosis
17 18	54	• Extensive dietary, lifestyle, medical, and HRQOL data at multiple time points after
19 20	55	diagnosis
21 22	56	• Availability of blood samples at 3 and 15 months after diagnosis, and formalin-fixed,
23 24 25	57	paraffin-embedded tumour tissue
25 26 27	58	Limited power for subgroup analyses
27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 960	59	

60 INTRODUCTION

Urinary bladder cancer (UBC) is the sixth most common cancer in the male population worldwide and tenth if considering both genders.[1] Approximately 75% of patients is diagnosed with non-muscle-invasive (NMIBC, stages Ta, T1, and Tis) and 25% with muscle-invasive (MIBC, stages T2, T3, and T4) bladder cancer.[2] Patients with NMIBC have a good survival but are at high risk for tumour recurrence and disease progression.[3] They are therefore subjected to frequent follow-up by cystoscopy and treatment. This makes bladder cancer the most expensive cancer in terms of health care expenditures per patient per year.[4] The high recurrence rate may also impact health-related guality of life (HRQOL).[5] Lifestyle factors have been linked to the prognosis and quality of life in patients with several cancer types [6, 7] but evidence in patients with NMIBC is scarce. If we can identify dietary and lifestyle habits that are related to the risk of recurrence and progression and HRQOL in patients with NMIBC, optimal interventions can be developed to improve their prognosis and HRQOL.

The primary risk factor for bladder cancer is smoking, which accounts for 43% of bladder cancer cases in men and 26% in women in Europe.[8] Other important risk factors for bladder cancer are occupational exposures to carcinogens like aromatic amines and polycyclic aromatic hydrocarbons (PAHs), family history, and specific low penetrance germline genetic variants.[9] Recent meta-analyses suggest that excess body weight [10] and physical inactivity [11] may also increase bladder cancer risk. The World Cancer Research Fund/American Institute for Cancer Research (The WCRF/AICR) report found probable evidence that arsenic in drinking water increases the risk of bladder, and limited suggestive evidence that higher consumption of fruit and vegetables and of tea decreases the risk of bladder cancer.[12] For other dietary and lifestyle factors, this report concluded that data were of too low quality, inconsistent, or the number of studies were insufficient to draw conclusions.[12]

Available evidence about the role of lifestyle habits on prognosis in patients with NMIBC is
 restricted to smoking [13, 14] and excess body weight.[15] A systematic review [13] and

Page 5 of 20

BMJ Open

recent meta-analysis of 10 studies including a total of 6,307 patients with NMIBC [14] found that current and former smokers at diagnosis had an approximately 25% increased risk of recurrence compared to never smokers. Our recent meta-analysis [15] of three studies [16-18] showed that overweight and obesity compared to normal weight at diagnosis were associated with increased risk of recurrence but not progression in patients with NMIBC, although power for progression was limited.[15] Smoking cessation and weight loss after diagnosis in relation to clinical outcomes has hardly been investigated. Evidence for other lifestyle habits, such as fluid intake and micturition, physical activity, and fruit and vegetable consumption, is very limited or not available.[15] Also, most studies on lifestyle and NMIBC prognosis included a heterogeneous study population with different tumour stages and grades of bladder cancer. However, NMIBC prognosis is clearly different for these subgroups [19] and may also differ by molecular subtype. [20, 21] Whether associations of lifestyle habits with NMIBC prognosis are mediated and/or modified by tumour stage and by molecular subtype has not yet been investigated.

Despite the high frequency of surveillance and repeated treatments, relatively little is known about the HRQOL of patients with NMIBC,[22] and research with validated bladder cancerspecific instruments is needed.[23] A systematic review of five studies on lifestyle and HRQOL in bladder cancer patients found some evidence for a positive association between physical activity and HRQOL, but insufficient evidence to draw any conclusions for consumption of fruit and vegetables or smoking cessation.[24]

There is a clear need to obtain more insight in the relation between lifestyle habits (and habit changes) and NMIBC outcomes and whether this relation is mediated and/or modified by tumour stage and molecular subtype. This information is essential to develop personalized evidence-based lifestyle advice for patients with NMIBC to improve their prognosis and quality of life. This would enable patients to get some control over their own disease course.

114 METHODS AND ANALYSIS

The UroLife study (Urothelial cell cancer: Lifestyle, prognosis, and quality of Life) is a prospective cohort study including patients with newly diagnosed NMIBC. The study has been designed to evaluate the association of dietary and lifestyle habits with risk of recurrence and progression and HRQOL. Patients are recruited in 22 hospitals in the East, South, and Central part of the Netherlands. Before the start of the study, permission was asked from all urologists of the participating hospitals to select and invite eligible patients from the Netherlands Cancer Registry (NCR), held by the Netherlands Comprehensive Cancer Organisation (IKNL). Once every 1 to 2 weeks, new patients are identified through IKNL using notification lists of the nationwide network and registry of histo- and cytopathology in the Netherlands (PALGA foundation). Approximately 4 weeks after diagnosis, patients are invited on behalf of their urologist to participate in this study. Patients who agree to participate provide a written informed consent.

128 Patient population

Eligible participants are Dutch speaking patients between 18 and 80 years old who are newly diagnosed with a histologically confirmed primary stage Ta, T1, and Tis NMIBC tumour and underwent a transurethral resection. Patients with a previous diagnosis of cancer in the past five years and those with a lymph node metastasis or distant metastasis are not eligible.

³ 133

- **Patient and public involvement**
- 135 Patients were not involved in the design, recruitment and conduct of the study.
- ¹⁹ 136
- **137** Data collection and management
- 4 138 *Questionnaires*

139 Participants are asked to complete self-administered web-based or paper-and-pencil-based
140 questionnaires at six weeks (T6wk), three months (T3mo), 15 months (T15mo), and 51
141 months (T51mo) after diagnosis (Figure 1, Table 1). Web-based questionnaires are collected

BMJ Open

using the data collection tool of the Patient Reported Outcomes Following Initial treatment
and Long term Evaluation of Survivorship (PROFILES) registry.[25] Follow-up telephone
calls are made to non-responding participants and to respondents whose questionnaires
have missing items.

The baseline questionnaire contains questions on demographics (age, sex, ethnicity, education, living situation, occupation, marital status) and (family) history of cancer. All questionnaires collect information about height, body weight, amount and frequency of alcohol consumption during week- and weekend days, smoking habits, comorbidities and the use of medication. Information on smoking habits is collected in detail, including age or date of starting and stopping smoking, number of cigarettes smoked per day, duration of smoking, and passive exposure to smoking. Information about habitual physical activity is collected by using the previously validated Short QUestionnaire to ASsess Health-enhancing physical activity (SQUASH),[26] which is fairly reliable and valid in an adult population.[26-28] The SQUASH questionnaire assesses the average time, i.e. number of days per week and hours and minutes per day, spent in commuting activities, leisure time activities, household activities, and activities at work in a normal week in the past month. At T3mo, T15mo, and T51mo, patients are also asked to measure and report their waist and hip circumference.

1 160

Habitual dietary intake is collected using a 163-item validated and reproducible self-administered food frequency questionnaire that was developed by Wageningen University.[29] The questionnaire contains questions about the frequency of consumption of food products and the portion size during the previous year (T6wk) or the previous months (T3mo, T15mo, and T51mo). Frequency and portion size of consumed food products are multiplied to obtain their intake in grams per day. Nutrient intake is calculated using the Dutch Food Composition Database (NEVO 2011).[30] Information about fluid intake and micturition is collected with a four-day diary at T3mo, T15mo en T51mo.

HRQOL is assessed at all four time points with the validated EORTC QLQ-C30 [31] and a 24-item module for patients with NMIBC, i.e. the EORTC QLQ-NMIBC24.[32] The EORTC QLQ-C30 contains five function scales (physical, role, cognitive, emotional and social functioning), three symptom scales (fatigue, nausea, pain and vomiting) and six single items (dyspnea, insomnia, loss of appetite, constipation, diarrhea, and financial impact), all scored from 1 (not at all) to 4 (very much)) and a global health status scale with ranges from 1 (very poor) to 7 (excellent). The EORTC QLQ-NMIBC24 contains six scales (urinary symptoms, malaise, future worries, bloating and flatulence, sexual function, and male sexual function) and five single items (intravesical treatment issues, sexual intimacy, risk of contaminating partner, sexual enjoyment, female sexual problems) scored from 1 (not at all) to 4 (very much). All scores will be linearly transformed to a 0 to 100 scale. Furthermore, at T3mo patients are asked to report whether they are aware of possible risk factors for (bladder) cancer, received lifestyle advice from their physician, and what their attitudes are towards physicians giving lifestyle advice.

Page 9 of 20		BMJ Open	bmjopen-2019-030396 c			
			n-20			
1 2 185	Table 1 Overview of data collection in Uro	l ife at the four time points)19-(
2 185 3		Included topics	OT6wk	T3mo	T15mo	T51mo
4	Questionnaires			151110	1151110	131110
5	Sociodemographic data	Date of birth, gender, living situation, marital status, country of birth of participant, father,	Sx Sx			
6	socioucinographic data	mother, race, highest level of education, working history, occupational exposure	ñ 16			
7		mother, race, nighest level of education, working history, occupational exposure	0			
8	Anthropometry	Height at diagnosis, weight two years before diagnosis, weight at age 18 years, average	October 2019.			
9	· · · · · · · · · · · · · · · · · · ·	weight during adult life	ber			
10		Current body weight, waist and hip circumference	NX	х	х	х
11			19			
12	Lifestyle	Current and past smoking behaviour, environmental smoke exposure	DX X	Х	Х	Х
13		Short Questionnaire to Assess Health-enhancing physical activity [26]	ŠΧ	Х	Х	Х
14		Frequency and amount of alcohol consumption during week and weekend days	<u>o</u> x	Х	Х	Х
15		Changes in eating habits and reasons for/type of changes	lde	Х	Х	Х
16			d fr			
17	Medical history	Previously diagnosed with cancer, family history of cancer	<u>B</u> x			
18		Comorbidities, medication use, dietary supplement use	₽X	Х	Х	Х
19			:p://			
20	Questions for females	Menstruation, menopause, use of contraceptives, use of hormone replacement therapy	đx	Х	Х	Х
21		Pregnancy	^b X			
22			en			
23	Diet	163- item Food Frequency Questionnaire	ğx	Х	Х	Х
24			<u>j</u> .c			
25	HRQOL	EORTC QLQ-C30 [31] and EORTC QLQ-NMIBC24 [32]	[₹] x	Х	Х	Х
26			on on			
27	Awareness risk factors and lifestyle advice	Awareness of cancer risk factors, received lifestyle advice, attitudes towards lifestyle advice	Ap	Х		
28	Four-day diary		Bownloaded from http://bmjopen.bmj.com/ on April 20,			
29		Frequency micturition, amount and type of fluid intake		Х	Х	Х
30	Blood		20			
31		EDTA whole blood for DNA isolation	24	х		
32		EDTA plasma, heparin plasma	2024 by gu	х	х	
33	Tissue					
34	Tissue	Formalin-fixed paraffin-embedded tissue of the primary tumour	st.			
35		Formalin-fixed paramit-embedded tissue of the primary tuniour	Ţ			
36 27	Clinical data		otec			
37		Disease characteristics, therapy	ξX	Х	Х	Х
38 39		Recurrence and progression	est. ^X Protected by		х	Х
39 40						
40 41			copyright.			
41		9	righ			
42			it.			
43		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml				
45						

Blood samples

Non-fasting blood samples are collected at T3mo and T15mo. At T3mo, 10 ml EDTA whole blood (for DNA isolation), 10 ml EDTA plasma and 10 ml heparin plasma is collected. At T15mo, 10 ml EDTA plasma and 10 ml heparin plasma is collected. Heparin plasma tubes are wrapped in aluminum foil to protect them from light. All blood samples are collected, processed and stored at -80°C locally in the participating hospitals according to a standard protocol before transportation on dry ice to the Radboud Biobank. The blood samples are stored in the Radboud Biobank at -80°C for future analyses of genetic and other biomarkers. Analysis of heparin plasma levels of nine biomarkers of fruit and vegetable consumption is planned. Concentration of six carotenoids (i.e. alpha-carotene, beta-carotene, beta-cryptoxanthin, lutein, lycopene and zeaxanthin), alpha-tocopherol, beta- and gamma-tocopherol and retinol were measured by HPLC (Thermo Scientific Accela LC system; Thermo Fisher Scientific) and analyzed by using ChromQuest 5.0, Version 3.2.1 software (Thermo Fisher Scientific).

Tumour samples

From patients diagnosed with T1 NMIBC, tumour specimens will be collected in two batches in 2019 and 2021. Tumour blocks will be identified by using the PALGA foundation and retrieved using the Dutch National Tissuebank Portal (DNTP) from the local pathology laboratories. Pathology review will be performed and tissue microarrays will be constructed. Molecular subtypes will be assessed by immunohistochemistry in 2021. As the development of a molecular classification system for NMIBC is still in progress and no consensus system is available yet, [33] we will use the most suitable evidence-based subtyping method that will then be available.

Clinical data

For all patients with NMIBC, information about disease characteristics and therapy for the initial tumour and subsequent recurrences is collected from the medical records by data

Page 11 of 20

BMJ Open

managers of the Netherlands Cancer Registry. Information about tumour characteristics includes incidence date, clinical (cTNM) and post-surgical (pTNM) stage,[34] tumour grade, concomitant carcinoma in situ, multifocality, number of tumours and histology. With respect to therapy, information is collected on type of cystoscopy (white or blue light) and on transurethral resection (TUR), i.e. date of TUR, presence of detrusor in the surgical specimen, and presence of lymphovascular invasion. Furthermore, data on local treatment (e.g., intravesical chemotherapy, BCG) with start and stop dates and, if applicable, on cystectomy (e.g., date, type) are collected.

Data on clinical outcomes, i.e. recurrence and progression with dates of diagnosis, stage andgrade, is also collected.

227 Power considerations & Data analysis

The association of lifestyle factors with risk of recurrence and progression will be evaluated by estimating hazard ratios and 95% confidence intervals using Cox proportional hazards regression analyses. All analyses will be adjusted for age, gender, tumour characteristics, and other potential confounders. Analytical techniques for longitudinal data and multiple outcomes will also be considered. Our power calculation is based on 1,100 patients who will be followed for five years. For comparing the highest (n=275) vs. lowest quartile (n=275) of a lifestyle factor (or vice versa), this study will be sufficiently powered (two-sided alpha=0.05, power 80%) to detect a hazard ratio of \geq 1.5 or \geq 1.3 (or \leq 0.7 or \leq 0.8) when assuming a five-year recurrence risk of 31% or 78%,[35] respectively.[36, 37] With an assumed loss to follow-up of 25% after five years, detectable hazard ratios will increase to \geq 1.6 or \geq 1.4 (or \leq 0.6 or ≤0.7), respectively. Lower hazard ratios can be detected when lifestyle factors are modeled continuously.

The association of lifestyle factors with HRQOL will be evaluated using longitudinal mixed
 model analyses, taking into account the within-subject variation in lifestyle and HRQOL over
 time and the between-subject variation. All analyses will be adjusted for age, gender, tumour

characteristics, and other potential confounders. Since we expect that the between-subject variation in lifestyle and HRQOL will be much larger than the within-subject variation, most information will come from the association observed between subjects and not from the association observed within subjects over time, Therefore, our power calculation is based on a cross-sectional correlation at one time point. With 825 patients (assuming a drop-out of 25%) and using 10 predictor variables, we have 80% power to detect a small correlation (Cohen's f² of 0.02).[38, 39] Power will be higher when using repeated measurements over time, especially when there is within-subject variation of lifestyle factors and HRQOL over time.

253 Cohort status

Medical ethical approval was obtained on 17 January 2014. Patient recruitment started in May 2014. Between 8 May 2014 and 25 April 2017, 2,133 patients with NMIBC initially diagnosed with Ta, T1, or Tis tumours have been identified and invited to participate in UroLife. Of these invited patients, 1,193 patients agreed to participate and 77 dropped out before filling out the first questionnaires (response rate 52%). Since May 2017, recruitment of patients with T1 (but not Ta or Tis) tumours has continued and is still ongoing. We aim to recruit a total of at least 700 patients with T1 bladder cancer, and the projected date of recruitment completion is April 2021.

^{.3} 262

DISCUSSION

The UroLife study is one of the largest multicenter prospective cohort studies on lifestyle and NMIBC outcomes worldwide. UroLife will provide new and comprehensive insights into whether lifestyle habits (or habit changes) are related to NMIBC outcomes and HRQOL, and whether these relations differ by tumour stage and molecular subtype. Unique features of UroLife are the recruitment of patients shortly after diagnosis, collection of extensive dietary, lifestyle, medical, and HRQOL data at multiple time points after diagnosis, collection of blood

BMJ Open

 (for DNA and biomarker analysis), and the availability of tumour tissue samples (formolecular classification).

As in many prospective cohort studies, non-participation and loss to follow may limit the generalizability of our findings. Although our study is large, we intend to combine our dataset in the future with other similar prospective studies in NMIBC to increase statistical power for subgroup analyses. Our ultimate aim is to provide personalized evidence-based lifestyle advice to patients with NMIBC, also according to tumour stage and molecular subtype, to enable them to have an influence on their clinical outcome.

2 279 ETHICS AND DISSEMINATION

The study protocol has been approved by the Committee for Human Research region Arnhem-Nijmegen (CMO 2013-494). Patients who agree to participate in the study provide written informed consent. The findings from our cohort study will be disseminated through peer-reviewed scientific journals, and presentations at (inter)national scientific meetings. Patients will be informed about the progress and results of this study through biannual newsletters and through the website of the study (https://www.radboudumc.nl/trials/urolife) and of the bladder cancer patient association (https://www.blaasofnierkanker.nl/). Also, presentations will be given at contact days of the bladder cancer patient association.

2 3 4	288	DECLARATIONS
4 5 6	289	
7 8	290	Authors' contributions
9 10	291	AV, LALMK, AJW, EK, and KKHA contributed to the conception and design of the study. AV
11 12	292	provides overall study management and coordinates the project. EW has contributed and
13 14	293	LdG contributes to data collection. LdG, EW and AV drafted the manuscript. All authors have
15 16 17	294	critically read and revised the manuscript. All authors approved the final version of the
17 18 19	295	manuscript.
20 21	296	
22 23	297	Funding
24 25	298	This work was supported by Alpe d'HuZes/Dutch Cancer Society (KUN 2013-5926) and
26 27	299	Dutch Cancer Society (Project no. 11179). Sponsors were not involved in the study design
28 29	300	nor will they be in the collection, analysis, and interpretation of data, or in the publications
30 31	301	that will result from this study.
32 33	302	
34 35 36	303	Competing interests
37 38	304	The authors declare that they have no competing interests.
39 40	305	
41 42	306	Availability of data and material
43 44	307	Data and material are not yet available since enrollment to the study is still ongoing and data
45 46	308	collection has not been completed yet. After completion of data collection, data will be made
47 48	309	available by the corresponding author upon reasonable request.
49 50	310	
51 52 53	311	Acknowledgements
55 55	312	We are grateful to all the patients who participate in this study and we would like to thank the
56 57	313	following hospitals for their involvement in recruitment for the UroLife study: Amphia
58 59	314	Ziekenhuis, Breda/Oosterhout (Drs. D.K.E. van der Schoot); Ziekenhuis Bernhoven, Uden
60	315	(Drs. A.Q.H.J. Niemer); Canisius-Wilhelmina Ziekenhuis, Nijmegen (Dr. D.M. Somford);

Page 15 of 20

BMJ Open

3 4	316	Catharina Ziekenhuis, Eindhoven (Dr. E.L. Koldewijn); Deventer Ziekenhuis, Deventer (Drs.
5 6	317	P.L.M. van den Tillaar); Elkerliek Ziekenhuis, Helmond (Drs. E.W. Stapper †, Drs. P.J. van
7 8	318	Hest); Gelre Ziekenhuizen, Apeldoorn/Zutphen (Drs. D.M. Bochove-Overgaauw); Isala
9 10	319	Klinieken, Zwolle (Dr. E. te Slaa); Jeroen Bosch Ziekenhuis, 's-Hertogenbosch (Dr. J.R.
11 12	320	Oddens; Dr. S. van der Meer); Meander Medisch Centrum, Amersfoort (Drs. F.S. van Rey);
13 14	321	Medisch Spectrum Twente, Enschede (Dr. M. Asselman); Maxima Medisch Centrum,
15 16	322	Veldhoven/Eindhoven (Dr. L.M.C.L. Fossion); Maasziekenhuis Pantein, Boxmeer (Drs. E.
17 18	323	van Boven); Radboudumc, Nijmegen (Prof. Dr. J.A. Witjes); Rijnstate,
19 20 21	324	Arnhem/Velp/Zevenaar (Drs. C.J. Wijburg); Slingeland Ziekenhuis, Doetinchem (Drs. A.D.H.
21 22 23	325	Geboers); St. Anna Ziekenhuis, Geldrop (Drs. A. Sonneveld); Elisabeth-TweeSteden
24 25	326	Ziekenhuis, Tilburg/Waalwijk (Dr. P.J.M. Kil); St. Jansdal Ziekenhuis, Harderwijk (Drs. W.J.
26 27	327	Kniestedt); VieCuri, Venlo (Drs. G. Yurdakul, Dr. A.H.P. Meier); Ziekenhuis Gelderse Vallei,
28 29	328	Ede (Drs. M.D.H. Kortleve); Ziekenhuisgroep Twente, Almelo/Hengelo (Dr. E.B. Cornel). In
30 31	329	addition, we thank Ms. Monique Eijgenberger for her assistance in data collection. We also
32 33	330	thank the data managers and research assistants of the Netherlands Cancer Registry held
34 35	331	by the Netherlands Comprehensive Cancer Organisation (IKNL) for inviting patients and
36 37	332	collecting the clinical data.
38 39 40 41	333	

REFERENCES

- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN 1. estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394-424.
- Babjuk M, Böhle A, Burger M, et al. EAU guidelines on non-muscle-invasive 2. urothelial carcinoma of the bladder: update 2016. Eur Urol 2017;71(3):447-61.
- 3. Cambier S, Sylvester RJ, Collette L, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin. Eur Urol 2016;69(1):60-9.
- 4. Sievert KD, Amend B, Nagele U, et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 2009;27(3):295-300.
- 5. Schmidt S, Francés A, Garin JAL, et al. Quality of life in patients with non-muscle-invasive bladder cancer: One-year results of a multicentre prospective cohort study. Urol Oncol 2015;33(1):19.e7-19.e15.
- Ligibel J. Lifestyle factors in cancer survivorship. J Clin Oncol 2012;30(30):3697-704. 6.
- 7. Mehra K, Berkowitz A, Sanft T. Diet, Physical Activity, and Body Weight in Cancer Survivorship. Med Clin North Am. 2017;101(6):1151-65.
- 8. van Osch FH, Jochems SH, van Schooten F-J, et al. Quantified relations between exposure to tobacco smoking and bladder cancer risk: a meta-analysis of 89 observational studies. Int J Epidemiol 2016;45(3):857-70.
- 9. Cumberbatch MGK, Jubber I, Black PC, et al. Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018. Eur Urol 2018;74(6):784-95.
- 10. Sun J-W, Zhao L-G, Yang Y, et al. Obesity and risk of bladder cancer: a dose-response meta-analysis of 15 cohort studies. PloS one 2015;10(3):e0119313.
 - 11. Keimling M, Behrens G, Schmid D, et al. The association between physical activity and bladder cancer: systematic review and meta-analysis. Br J Cancer 2014;110(7):1862-70.
- 12. World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project Expert Report 2018: Diet, nutrition, physical activity and bladder cancer. 2018, https://www.wcrf.org/dietandcancer
- 13. Crivelli JJ, Xylinas E, Kluth LA, et al. Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature. Eur Urol 2014;65(4):742-54.
- 14. Hou L, Hong X, Dai M, et al. Association of smoking status with prognosis in bladder cancer: A meta-analysis. Oncotarget 2017;8(1):1278-89.
- 15. Westhoff E, Witjes JA, Fleshner NE, et al. Body Mass Index, Diet-Related Factors, and Bladder Cancer Prognosis: A Systematic Review and Meta-Analysis. Bladder Cancer 2018;4(1):91-112.

1 2			
2 3	388		
4	389	16.	Kluth LA, Xylinas E, Crivelli JJ, et al. Obesity is associated with worse outcomes in
5 6	390 391		patients with T1 high grade urothelial carcinoma of the bladder. J Urol
7	391 392		2013;190(2):480-6.
8 9	393 394	17.	Wyszynski A, Tanyos SA, Rees JR, et al. Body mass and smoking are modifiable risk factors for recurrent bladder cancer. <i>Cancer</i> 2014;120(3):408-14.
10	395		
11 12 13	396 397	18.	Xu T, Zhu Z, Wang X, et al. Impact of body mass on recurrence and progression in Chinese patients with Ta, T1 urothelial bladder cancer. <i>Int Urol Nephrol</i>
13 14 15	398 399		2015;47(7):1135-41.
15 16 17	400 401	19.	van der Heijden AG, Witjes JA. Recurrence, progression, and follow-up in non- muscle-invasive bladder cancer. <i>Eur Urol Suppl</i> 2009;8(7):556-62.
18	402		
19 20	403 404	20.	Sjödahl G, Lauss M, Lövgren K, et al. A molecular taxonomy for urothelial carcinoma. <i>Clin Cancer Res</i> 2012;18:3377-86.
21 22	405	04	Detection O. Oikidebl. O. Obabil. O. et al. A made culor mathelastic formation for risk
22 23 24	406 407	21.	Patschan O, Sjödahl G, Chebil G, et al. A molecular pathologic framework for risk stratification of stage T1 urothelial carcinoma. <i>Eur Urol</i> 2015;68(5):824-32.
25	408 409	22.	Jung A, Nielsen ME, Crandell JL, et al. Quality of Life in Non-Muscle-Invasive Bladder
26	410	22.	Cancer Survivors: A Systematic Review. <i>Cancer Nurs</i> Published Online First: 1 June
27	411		2018. doi:10.1097/NCC.00000000000606.
28 29	412		
29 30	413	23.	Mohamed N, Gilbert F, Lee C, et al. Pursuing Quality in the application of bladder
31	414		Cancer quality of Life Research. <i>Bladder Cancer</i> 2016;2(2):139-49.
32	415	0.4	Operate brickers A. Langer TA. Frankright at all lifesteds frankright and bealth related
33	416	24.	Gopalakrishna A, Longo TA, Fantony JJ, et al. Lifestyle factors and health-related
34 35	417 418		quality of life in bladder cancer survivors: a systematic review. <i>J Cancer Surviv</i> 2016;10(5):874-82.
36	419	~-	
37	420	25.	van de Poll-Franse LV, Horevoorts N, van Eenbergen M, et al. The Patient Reported
38	421		Outcomes Following Initial treatment and Long term Evaluation of Survivorship
39 40	422 423		registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. <i>Eur J Cancer</i>
40 41	423 424		2011;47(14):2188-94.
42	425		2011,47(14).2100 04.
43	426	26.	Wendel-Vos GW, Schuit AJ, Saris WH, et al. Reproducibility and relative validity of
44	427	-	the short questionnaire to assess health-enhancing physical activity. J Clin Epidemiol
45	428		2003;56(12):1163-9.
46	429		
47 48	430	27.	de Hollander EL, Zwart L, de Vries SI, et al. The SQUASH was a more valid tool than
40 49	431		the OBiN for categorizing adults according to the Dutch physical activity and the
50	432		combined guideline. <i>J Clin Epidemiol</i> 2012;65(1):73-81.
51	433	~~	
52	434	28.	Wagenmakers R, van den Akker-Scheek I, Groothoff JW, et al. Reliability and validity
53	435		of the short questionnaire to assess health-enhancing physical activity (SQUASH) in
54	436 437		patients after total hip arthroplasty. BMC Musculoskelet Disord 2008;9(1):141.
55 56	437	29.	Siebelink E, Geelen A, de Vries JH. Self-reported energy intake by FFQ compared
50 57	439	20.	with actual energy intake to maintain body weight in 516 adults. Br J Nutr
58	440		2011;106(2):274-81.
59	441		
60			

- 3 442 30. NEVO-tabel (2011) Dutch Food Composition Database. Den Haag: 4 443 RIVM/Voedingscentrum. 5 444
- 445 445 445 446
 446 8 447 447
 9 448 447
 448 447
 448 447
 448 447
 448 447
 448 447
 448 447
 448 448
- Here
 <li
- 452
 453
 453
 454
 454
 454
 454
 455
 455
 Chandrasekar T, Erlich A, Zlotta AR. Molecular Characterization of Bladder Cancer.
 454
 Curr Urol Rep 2018;19(12):107.
- 455
 456
 456
 457
 457
 457
 458
 458
 458
 455
 458
 455
 455
 456
 457
 457
 457
 457
 457
 457
 457
 458
 458
 458
 458
- 459
 460
 460
 461
 462
 462
 463
 35. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. *Eur Urol* 2006;49(3):466-77.
- 464
 464
 465
 465
 465
 466
 466
- 467
 467
 47
 468
 468
 469
 469
 470
- 470
 471
 471
 38. Faul F, Erdfelder E, Buchner A, et al. Statistical power analyses using G* Power 3.1: Tests for correlation and regression analyses. *Behav Res Methods* 2009;41(4):1149-60.
 474
- 474
 475
 475
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476

- 43 478
- 44 45
- 46 47

- 48 49
- 50 51
- 52

53 54


55 56

57

58 59

1		
2 3	479	FIGURE LEGENDS
4 5	480	Figure 1 Timeline and study design of the UroLife study.
6 7		
8 9		
10		
11 12		
13 14		
15 16		
17 18		
19		
20 21		
22 23		
24 25		
26 27		
28 29		
30 31		
32 33		
34		
35 36		
37 38		
39 40		
41 42		
43 44		
45 46		
47 48		
49		
50 51		
52 53		
54 55		
56 57		
58 59		
60		

Page 20 of 20






Figure 1 Timeline and study design of the UroLife study.

The UroLife study: Protocol for a Dutch prospective cohort on lifestyle habits in relation to non-muscle-invasive bladder cancer prognosis and health-related quality of life

Journal:	BMJ Open
Manuscript ID	bmjopen-2019-030396.R1
Article Type:	Protocol
Date Submitted by the Author:	27-Aug-2019
Complete List of Authors:	de Goeij, Liesbeth; Radboudumc, Department for Health Evidence Westhoff, Ellen; Radboudumc, Department for Health Evidence Witjes, JA; Radboudumc, Department of Urology Aben, Katja; Netherlands Comprehensive Cancer Organisation; Radboudumc, Department for Health Evidence Kampman, Ellen; Wageningen University Kiemeney, Lambertus; Radboudumc, Department for Health Evidence Vrieling, Alina; Radboudumc, Department for Health Evidence
Primary Subject Heading :	Urology
Secondary Subject Heading:	Epidemiology
Keywords:	Urological tumours < ONCOLOGY, EPIDEMIOLOGY, NUTRITION & DIETETICS



2		
3 4	1	The UroLife study: Protocol for a Dutch prospective cohort on lifestyle habits in
5 6	2	relation to non-muscle-invasive bladder cancer prognosis and health-related quality of
7 8	3	life
9 10	4	
11 12	5	Liesbeth de Goeij ^a , Ellen Westhoff ^a , J. Alfred Witjes ^b , Katja K.H. Aben ^{a,c} , Ellen Kampman ^d ,
13 14	6	Lambertus A.L.M. Kiemeney ^{a,b} , Alina Vrieling ^{a*}
15 16	7	
17 18 10	8	^a Radboud university medical center, Radboud Institute for Health Sciences, Nijmegen, The
19 20 21 22	9	Netherlands
22 23 24	10	^b Radboud University Nijmegen Medical Center, Department of Urology, Nijmegen, The
25 26	11	Netherlands
27 28 29	12	° Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands
30 31 32	13	^d Wageningen University, Division of Human Nutrition and Health, Wageningen, The
33 34	14	Netherlands
35 36 37	15	
38 39	16	*Corresponding author: Dr. Alina Vrieling, Radboud university medical center, Department
40 41 42	17	for Health Evidence (Mailbox 133), P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.
43 44	18	Tel: +31 24 3616944, Fax: +31 24 3613505, e-mail: Alina.Vrieling@radboudumc.nl
45 46 47	19	
48 49	20	Word count: 3040
50 51 52 53 54 55 56 57 58 59 60	21	

22 ABSTRACT

23 Introduction:

Patients with non-muscle-invasive bladder cancer (NMIBC) have a good survival but are at high risk for tumour recurrence and disease progression. It is important to identify lifestyle habits that may reduce the risk of recurrence and progression and improve health-related quality of life (HRQOL). This paper describes the rationale and design of the UroLife study. The main aim of this study is to evaluate whether lifestyle habits are related to prognosis and HRQOL in patients with NMIBC.

30 Methods and analysis:

The UroLife study is a multi-centre prospective cohort study among more than 1,100 newly diagnosed patients with NMIBC recruited from 22 hospitals in the Netherlands. At six weeks and three, 15, and 51 months after diagnosis, participants fill out a general questionnaire, and questionnaires about their lifestyle habits and HRQOL. At three, 15, and 51 months after diagnosis, information about fluid intake and micturition is collected with a four-day diary. At three and 15 months after diagnosis, patients donate blood samples for DNA extraction and (dietary) biomarker analysis. Tumour samples are collected from all patients with T1 disease to assess molecular subtypes. Information about disease characteristics and therapy for the primary tumour and subsequent recurrences is collected from the medical records by the Netherlands Cancer Registry. Statistical analyses will be adjusted for age, gender, tumour characteristics and other known confounders.

42 Ethics and dissemination:

47
43 The study protocol has been approved by the Committee for Human Research region
49
44 Arnhem-Nijmegen (CMO 2013-494). Patients who agree to participate in the study provide
45 written informed consent. The findings from our study will be disseminated through peer46 reviewed scientific journals and presentations at (inter)national scientific meetings. Patients
47 will be informed about the progress and results of this study through biannual newsletters
48 and through the website of the study and of the bladder cancer patient association.

1 2		
2 3 4	50	Keywords: bladder cancer, diet, lifestyle, biomarkers, recurrence, prognosis, quality of life,
5 6 7	51	cohort, study protocol
8 9	52	
10 11 12	53	STRENGTHS AND LIMITATIONS OF THIS STUDY
12 13 14	54	Large multicenter prospective cohort study of NMIBC patients recruited shortly after
15 16	55	diagnosis
17 18	56	• Extensive dietary, lifestyle, medical, and HRQOL data at multiple time points after
19 20	57	diagnosis
21 22	58	• Availability of blood samples at 3 and 15 months after diagnosis, and formalin-fixed,
23 24 25	59	paraffin-embedded tumour tissue
25 26 27	60	Limited power for subgroup analyses
28 29	61	 Loss to follow-up potentially influencing validity of results
30 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 950 51 52 53 54 55 56 57 58 59 60	62	

63 INTRODUCTION

Urinary bladder cancer is the sixth most common cancer in the male population worldwide and tenth if considering both genders.[1] Approximately 75% of patients is diagnosed with non-muscle-invasive (NMIBC, stages Ta, T1, and Tis) and 25% with muscle-invasive (MIBC, stages T2, T3, and T4) bladder cancer.[2] Patients with NMIBC have a good survival but are at high risk for tumour recurrence and disease progression.[3] They are therefore subjected to frequent follow-up by cystoscopy and treatment. This makes bladder cancer the most expensive cancer in terms of health care expenditures per patient per year.[4] The high recurrence rate may also impact health-related guality of life (HRQOL).[5] Lifestyle factors have been linked to the prognosis and quality of life in patients with several cancer types [6, 7] but evidence in patients with NMIBC is scarce. If we can identify lifestyle habits that are related to the risk of recurrence and progression and HRQOL in patients with NMIBC, optimal interventions can be developed to improve their prognosis and HRQOL.

The primary risk factor for bladder cancer is smoking, which accounts for 43% of bladder cancer cases in men and 26% in women in Europe.[8] Other important risk factors for bladder cancer are occupational exposures to carcinogens like aromatic amines and polycyclic aromatic hydrocarbons (PAHs), family history, and specific low penetrance germline genetic variants.[9] Recent meta-analyses suggest that excess body weight [10] and physical inactivity [11] may also increase bladder cancer risk. The World Cancer Research Fund/American Institute for Cancer Research (The WCRF/AICR) report found probable evidence that arsenic in drinking water increases the risk of bladder, and limited suggestive evidence that higher consumption of fruit and vegetables and of tea decreases the risk of bladder cancer.[12] For other dietary and lifestyle factors, this report concluded that data were of too low quality, inconsistent, or the number of studies were insufficient to draw conclusions.[12]

Available evidence about the role of lifestyle habits on prognosis in patients with NMIBC is
 restricted to smoking [13, 14] and excess body weight.[15] A systematic review [13] and
 recent meta-analysis of 10 studies including a total of 6,307 patients with NMIBC [14] found

Page 5 of 20

BMJ Open

that current and former smokers at diagnosis had an approximately 25% increased risk of recurrence compared to never smokers. Our recent meta-analysis [15] of three studies [16-18] showed that overweight and obesity compared to normal weight at diagnosis were associated with increased risk of recurrence but not progression in patients with NMIBC, although power for progression was limited.[15] Smoking cessation and weight loss after diagnosis in relation to clinical outcomes has hardly been investigated. Evidence for other lifestyle habits, such as fluid intake and micturition, physical activity, and fruit and vegetable consumption, is very limited or not available.[15] Also, most studies on lifestyle and NMIBC prognosis included a heterogeneous study population with different tumour stages and grades of bladder cancer. However, NMIBC prognosis is clearly different for these subgroups [19] and may also differ by molecular subtype. [20, 21] Whether associations of lifestyle habits with NMIBC prognosis are mediated and/or modified by tumour stage and by molecular subtype has not yet been investigated.

104 Despite the high frequency of surveillance and repeated treatments, relatively little is known
 about the HRQOL of patients with NMIBC,[22] and research with validated bladder cancer specific instruments is needed.[23] A systematic review of five studies on lifestyle and
 HRQOL in bladder cancer patients found some evidence for a positive association between
 physical activity and HRQOL, but insufficient evidence to draw any conclusions for
 consumption of fruit and vegetables or smoking cessation.[24]

The aim of our study is to evaluate the association of pre- and post-diagnosis lifestyle habits (and habit changes) with risk of recurrence and progression and HRQOL. Also, we want to explore whether this association is mediated and/or modified by tumour stage and molecular subtype.

115 METHODS AND ANALYSIS

The UroLife study (Urothelial cell cancer: Lifestyle, prognosis, and quality of Life) is a prospective cohort study including patients with newly diagnosed NMIBC. The study has been designed to evaluate the association of lifestyle habits with risk of recurrence and progression and HRQOL. Patients are recruited in 22 hospitals in the East, South, and Central part of the Netherlands. Before the start of the study, permission was asked from all urologists of the participating hospitals to select and invite eligible patients from the Netherlands Cancer Registry (NCR), held by the Netherlands Comprehensive Cancer Organisation (IKNL). Once every 1 to 2 weeks, new patients are identified through IKNL using notification lists of the nationwide network and registry of histo- and cytopathology in the Netherlands (PALGA foundation). Approximately 4 weeks after diagnosis, patients are invited on behalf of their urologist to participate in this study. Patients who agree to participate provide a written informed consent.

129 Patient population

Eligible participants are Dutch speaking patients between 18 and 80 years old who are newly diagnosed with a histologically confirmed primary stage Ta, T1, and Tis NMIBC tumour and underwent a transurethral resection. Patients with a previous diagnosis of cancer in the past five years and those with a lymph node metastasis or distant metastasis are not eligible.

- ⁴⁵ 135 Patient and public involvement
 ⁴⁶
- ⁴⁷ 136 Patients were not involved in the design, recruitment and conduct of the study.
- 51138Data collection and management
- 54 139 *Questionnaires*

Participants are asked to complete self-administered web-based or paper-and-pencil-based
questionnaires at six weeks (T6wk), three months (T3mo), 15 months (T15mo), and 51
months (T51mo) after diagnosis (Figure 1, Table 1). Web-based questionnaires are collected

BMJ Open

using the data collection tool of the Patient Reported Outcomes Following Initial treatment
and Long term Evaluation of Survivorship (PROFILES) registry.[25] Follow-up telephone
calls are made to non-responding participants and to respondents whose questionnaires
have missing items.

The baseline questionnaire contains questions on demographics (age, sex, ethnicity, education, living situation, occupation, marital status) and (family) history of cancer. All questionnaires collect information about height, body weight, amount and frequency of alcohol consumption during week- and weekend days, smoking habits, comorbidities and the use of medication. Information on smoking habits is collected in detail, including age or date of starting and stopping smoking, number of cigarettes smoked per day, duration of smoking, and passive exposure to smoking. Information about habitual physical activity is collected by using the previously validated Short QUestionnaire to ASsess Health-enhancing physical activity (SQUASH),[26] which is fairly reliable and valid in an adult population.[26-28] The SQUASH questionnaire assesses the average time, i.e. number of days per week and hours and minutes per day, spent in commuting activities, leisure time activities, household activities, and activities at work in a normal week in the past month. At T3mo, T15mo, and T51mo, patients are also asked to measure and report their waist and hip circumference.

1 161

Habitual dietary intake is collected using a 163-item validated and reproducible self-administered food frequency questionnaire that was developed by Wageningen University.[29] The questionnaire contains questions about the frequency of consumption of food products and the portion size during the previous year (T6wk) or the previous months (T3mo, T15mo, and T51mo). Frequency and portion size of consumed food products are multiplied to obtain their intake in grams per day. Nutrient intake is calculated using the Dutch Food Composition Database (NEVO 2011).[30] Information about fluid intake and micturition is collected with a four-day diary at T3mo, T15mo en T51mo.

HRQOL is assessed at all four time points with the validated European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 [31] and a 24-item module for patients with NMIBC, i.e. the EORTC QLQ-NMIBC24.[32] The EORTC QLQ-C30 contains five function scales (physical, role, cognitive, emotional and social functioning), three symptom scales (fatigue, nausea, pain and vomiting) and six single items (dyspnea, insomnia, loss of appetite, constipation, diarrhea, and financial impact), all scored from 1 (not at all) to 4 (very much)) and a global health status scale with ranges from 1 (very poor) to 7 (excellent). The EORTC QLQ-NMIBC24 contains six scales (urinary symptoms, malaise, future worries, bloating and flatulence, sexual function, and male sexual function) and five single items (intravesical treatment issues, sexual intimacy, risk of contaminating partner, sexual enjoyment, female sexual problems) scored from 1 (not at all) to 4 (very much). All scores will be linearly transformed to a 0 to 100 scale.

> Furthermore, at T3mo patients are asked to report whether they are aware of possible risk factors for (bladder) cancer, received lifestyle advice from their physician, and what their attitudes are towards physicians giving lifestyle advice.

Page 9 of 20		BMJ Open	bmjopen-2019-030396 c			
			en-20			
1 2 187	Table 1 Overview of data collection in Uro	Life at the four time points)19-(
2 187 3		Included topics	OT6wk	T3mo	T15mo	T51mo
4	Questionnaires			151110	1151110	131110
5	Sociodemographic data	Date of birth, gender, living situation, marital status, country of birth of participant, father,	Sx Sx			
6	Sociouemographic data	mother, race, highest level of education, working history, occupational exposure	n 16			
7		mother, race, highest level of education, working history, occupational exposure	0 0			
8	Anthropometry	Height at diagnosis, weight two years before diagnosis, weight at age 18 years, average	October 2019.			
9	, intil openietry	weight during adult life	ber			
10		Current body weight, waist and hip circumference	NX	Х	х	х
11			9			
12	Lifestyle	Current and past smoking behaviour, environmental smoke exposure		Х	Х	Х
13		Short Questionnaire to Assess Health-enhancing physical activity [26]	≦x	Х	Х	Х
14		Frequency and amount of alcohol consumption during week and weekend days	<u>o</u> x	Х	Х	Х
15		Changes in eating habits and reasons for/type of changes	ade	Х	Х	Х
16			ă f			
17	Medical history	Previously diagnosed with cancer, family history of cancer	дx			
18		Comorbidities, medication use, dietary supplement use	ΞX	Х	Х	Х
19			tp:/			
20	Questions for females	Menstruation, menopause, use of contraceptives, use of hormone replacement therapy	gx	Х	Х	Х
21		Pregnancy	<u>д</u> х			
22			ben			
23	Diet	163- item Food Frequency Questionnaire	<u></u> x	Х	Х	Х
24			-j. .0			
25	HRQOL	EORTC QLQ-C30 [31] and EORTC QLQ-NMIBC24 [32]	Bx	Х	Х	Х
26			or			
27	Awareness risk factors and lifestyle advice	Awareness of cancer risk factors, received lifestyle advice, attitudes towards lifestyle advice	Ā	Х		
28	Four-day diary	Bownlöaded fröm http://bmjöpen.bmj.com/ on April 20,				
29		Frequency micturition, amount and type of fluid intake	20,	х	х	Х
30	Blood					
31	2.002	EDTA whole blood for DNA isolation	24	х		
32		EDTA plasma, heparin plasma	2024 by gu	X	х	
33	T ¹					
34	Tissue	Formalis fixed poweffic and added tions of the asimomy type out	est.			
35		Formalin-fixed paraffin-embedded tissue of the primary tumour	ਧੂ			
36	Clinical data		ote			
37		Disease characteristics, therapy	Sex 2	х	Х	Х
38		Recurrence and progression	est. Protected by		Х	Х
39 40						
40 41			copyright			
41 42		9	righ			
42 43			.t.			
43 44		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml				
45						
- -						

Blood samples

Non-fasting blood samples are collected at T3mo and T15mo. At T3mo, 10 ml EDTA whole blood (for DNA isolation), 10 ml EDTA plasma and 10 ml heparin plasma is collected. At T15mo, 10 ml EDTA plasma and 10 ml heparin plasma is collected. Heparin plasma tubes are wrapped in aluminum foil to protect them from light. All blood samples are collected, processed and stored at -80°C locally in the participating hospitals according to a standard protocol before transportation on dry ice to the Radboud Biobank. The blood samples are stored in the Radboud Biobank at -80°C for future analyses of genetic and other biomarkers. Analysis of heparin plasma levels of nine biomarkers of fruit and vegetable consumption is planned. Concentration of six carotenoids (i.e. alpha-carotene, beta-carotene, beta-cryptoxanthin, lutein, lycopene and zeaxanthin), alpha-tocopherol, beta- and gamma-tocopherol and retinol were measured by HPLC (Thermo Scientific Accela LC system; Thermo Fisher Scientific) and analyzed by using ChromQuest 5.0, Version 3.2.1 software (Thermo Fisher Scientific).

Tumour samples

From patients diagnosed with T1 NMIBC, tumour specimens will be collected in two batches in 2019 and 2021. Tumour blocks will be identified by using the PALGA foundation and retrieved using the Dutch National Tissuebank Portal (DNTP) from the local pathology laboratories. Pathology review will be performed and tissue microarrays will be constructed. Molecular subtypes will be assessed by immunohistochemistry in 2021. As the development of a molecular classification system for NMIBC is still in progress and no consensus system is available yet, [33] we will use the most suitable evidence-based subtyping method that will then be available.

Clinical data

For all patients with NMIBC, information about disease characteristics and therapy for the initial tumour is collected from the medical records by data managers of the Netherlands

Page 11 of 20

BMJ Open

Cancer Registry. Information about tumour characteristics includes incidence date, clinical (cTNM) and post-surgical (pTNM) stage,[34] tumour grade, concomitant carcinoma in situ, multifocality, number of tumours and histology. With respect to therapy, information is collected on type of cystoscopy (white or blue light) and on transurethral resection (TUR), i.e. date of TUR, presence of detrusor in the surgical specimen, and presence of lymphovascular invasion. Furthermore, data on local treatment (e.g., intravesical chemotherapy, BCG) with start and stop dates and, if applicable, on cystectomy (e.g., date, type) are collected.

Data on clinical outcomes, i.e. recurrence and progression, with dates of diagnosis, tumour characteristics, and therapy is also collected from the medical records by data managers of the Netherlands Cancer Registry. Information on vital status is collected by linkage with the Personal Records Database. All patients will be followed for at least 5 years.

Power considerations & Data analysis

Risk of recurrence (or progression) will be evaluated as time to first recurrence (or progression). The association of pre- and post-diagnostic lifestyle factors, as well as changes in lifestyle factors, with risk of recurrence and progression will be evaluated by estimating hazard ratios and 95% confidence intervals using Cox proportional hazards regression analyses. All analyses will be adjusted for age, gender, tumour characteristics, and other known confounders. Analytical techniques for longitudinal data and multiple outcomes will also be explored and applied. Our power calculation is based on 1,100 patients who will be followed for five years. For comparing the highest (n=275) vs. lowest guartile (n=275) of a lifestyle factor (or vice versa), this study will be sufficiently powered (two-sided alpha=0.05, power 80%) to detect a hazard ratio of \geq 1.5 or \geq 1.3 (or \leq 0.7 or \leq 0.8) when assuming a five-year recurrence risk of 31% or 78%,[35] respectively.[36, 37] With an assumed loss to followup of 25% after five years, detectable hazard ratios will increase to \geq 1.6 or \geq 1.4 (or \leq 0.6 or \leq 0.7), respectively. Lower hazard ratios can be detected when lifestyle factors are modeled continuously.

The association of lifestyle factors with HRQOL will be evaluated using longitudinal mixed model analyses, taking into account the within-subject variation in lifestyle and HRQOL over time and the between-subject variation. All analyses will be adjusted for age, gender, tumour characteristics, and other known confounders. Since we expect that the between-subject variation in lifestyle and HRQOL will be much larger than the within-subject variation, most information will come from the association observed between subjects and not from the association observed within subjects over time, Therefore, our power calculation is based on a cross-sectional correlation at one time point. With 825 patients (assuming a loss to followup of 25%) and using 10 predictor variables, we have 80% power to detect a small correlation (Cohen's f² of 0.02).[38, 39] Power will be higher when using repeated measurements over time, especially when there is within-subject variation of lifestyle factors and HRQOL over time.

° 257

258 Cohort status

Medical ethical approval was obtained on 17 January 2014. Patient recruitment started in May 2014. Between 8 May 2014 and 25 April 2017, 2,133 patients with NMIBC initially diagnosed with Ta, T1, or Tis tumours have been identified and invited to participate in UroLife. Of these invited patients, 1,193 patients agreed to participate and 77 dropped out before filling out the first questionnaires (response rate 52%). Since May 2017, recruitment of patients with T1 (but not Ta or Tis) tumours has continued and is still ongoing. We aim to recruit a total of at least 700 patients with T1 bladder cancer, and the projected date of recruitment completion is April 2021.

268 DISCUSSION

The UroLife study is one of the largest multicenter prospective cohort studies on lifestyle and NMIBC outcomes worldwide. UroLife will provide new and comprehensive insights into whether lifestyle habits (or habit changes) are related to NMIBC outcomes and HRQOL, and whether these relations differ by tumour stage and molecular subtype. Unique features of Page 13 of 20

 BMJ Open

UroLife are the recruitment of patients shortly after diagnosis, collection of extensive dietary, lifestyle, medical, and HRQOL data at multiple time points after diagnosis, collection of blood (for DNA and biomarker analysis), and the availability of tumour tissue samples (for molecular classification).

As in many prospective cohort studies, non-participation may limit the generalisability of our findings. In addition, loss to follow-up may limit the validity of our findings. Information bias due to reliance on recall and self-report, or due to missing data, may be another potential limitation. Although our study is large, we intend to combine our dataset in the future with other similar prospective studies in NMIBC to increase statistical power for subgroup analyses.

If the results of this study show that lifestyle factors are associated with clinical outcomes in NMIBC patients and these results are confirmed by other prospective studies or randomised trials, lifestyle recommendations and lifestyle interventions can be developed. Patients diagnosed with NMIBC could then be advised by their physician about their lifestyle and/or referred to a lifestyle intervention (e.g. smoking cessation program, exercise program). Thus, our ultimate aim is to provide personalized evidence-based lifestyle advice to patients with NMIBC, also according to tumour stage and molecular subtype, to enable them to have an influence on their clinical outcome.

ETHICS AND DISSEMINATION

The study protocol has been approved by the Committee for Human Research region Arnhem-Nijmegen (CMO 2013-494). Patients who agree to participate in the study provide written informed consent. The findings from our cohort study will be disseminated through peer-reviewed scientific journals, and presentations at (inter)national scientific meetings. Patients will be informed about the progress and results of this study through biannual newsletters and through the website of the study (https://www.radboudumc.nl/trials/urolife) and of the bladder cancer patient association (https://www.blaasofnierkanker.nl/). Also, presentations will be given at contact days of the bladder cancer patient association.

2 3 4	301	DECLARATIONS
5 6 7 8 9 10	302	
	303	Authors' contributions
	304	AV, LALMK, AJW, EK, and KKHA contributed to the conception and design of the study. AV
11 12	305	provides overall study management and coordinates the project. EW has contributed and
13 14	306	LdG contributes to data collection. LdG, EW and AV drafted the manuscript. All authors have
15 16	307	critically read and revised the manuscript. All authors approved the final version of the
 17 18 19 20 21 22 23 24 25 	308	manuscript.
	309	
	310	Funding
	311	This work was supported by Alpe d'HuZes/Dutch Cancer Society (KUN 2013-5926) and
26 27	312	Dutch Cancer Society (Project no. 11179). Sponsors were not involved in the study design
28 29 30 31 32 33 34 35 36 37 38 39 40 41 42	313	nor will they be in the collection, analysis, and interpretation of data, or in the publications
	314	that will result from this study.
	315	
	316	Competing interests
	317	The authors declare that they have no competing interests.
	318	
	319	Availability of data and material
43 44	320	Data and material are not yet available since enrollment to the study is still ongoing and data
45 46	321	collection has not been completed yet. After completion of data collection, data will be made
47 48	322	available by the corresponding author upon reasonable request.
49 50	323	
51 52	324	Acknowledgements
53 54 55	325	We are grateful to all the patients who participate in this study and we would like to thank the
56 57	326	following hospitals for their involvement in recruitment for the UroLife study: Amphia
58 59	327	Ziekenhuis, Breda/Oosterhout (Drs. D.K.E. van der Schoot); Ziekenhuis Bernhoven, Uden
60	328	(Drs. A.Q.H.J. Niemer); Canisius-Wilhelmina Ziekenhuis, Nijmegen (Dr. D.M. Somford);

Page 15 of 20

BMJ Open

3 4	329	Catharina Ziekenhuis, Eindhoven (Dr. E.L. Koldewijn); Deventer Ziekenhuis, Deventer (Drs.
5 6	330	P.L.M. van den Tillaar); Elkerliek Ziekenhuis, Helmond (Drs. E.W. Stapper †, Drs. P.J. van
7 8	331	Hest); Gelre Ziekenhuizen, Apeldoorn/Zutphen (Drs. D.M. Bochove-Overgaauw); Isala
9 10	332	Klinieken, Zwolle (Dr. E. te Slaa); Jeroen Bosch Ziekenhuis, 's-Hertogenbosch (Dr. J.R.
11 12	333	Oddens; Dr. S. van der Meer); Meander Medisch Centrum, Amersfoort (Drs. F.S. van Rey);
13 14	334	Medisch Spectrum Twente, Enschede (Dr. M. Asselman); Maxima Medisch Centrum,
15 16	335	Veldhoven/Eindhoven (Dr. L.M.C.L. Fossion); Maasziekenhuis Pantein, Boxmeer (Drs. E.
 17 18 19 20 21 22 23 24 25 	336	van Boven); Radboudumc, Nijmegen (Prof. Dr. J.A. Witjes); Rijnstate,
	337	Arnhem/Velp/Zevenaar (Drs. C.J. Wijburg); Slingeland Ziekenhuis, Doetinchem (Drs. A.D.H.
	338	Geboers); St. Anna Ziekenhuis, Geldrop (Drs. A. Sonneveld); Elisabeth-TweeSteden
	339	Ziekenhuis, Tilburg/Waalwijk (Dr. P.J.M. Kil); St. Jansdal Ziekenhuis, Harderwijk (Drs. W.J.
26 27	340	Kniestedt); VieCuri, Venlo (Drs. G. Yurdakul, Dr. A.H.P. Meier); Ziekenhuis Gelderse Vallei,
28 29	341	Ede (Drs. M.D.H. Kortleve); Ziekenhuisgroep Twente, Almelo/Hengelo (Dr. E.B. Cornel). In
30 31	342	addition, we thank Ms. Monique Eijgenberger for her assistance in data collection. We also
32 33	343	thank the data managers and research assistants of the Netherlands Cancer Registry held
34 35	344	by the Netherlands Comprehensive Cancer Organisation (IKNL) for inviting patients and
36 37 38 39 40	345	collecting the clinical data.
	346	

REFERENCES


- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN 1. estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394-424.
- Babjuk M, Böhle A, Burger M, et al. EAU guidelines on non-muscle-invasive 2. urothelial carcinoma of the bladder: update 2016. Eur Urol 2017;71(3):447-61.
- Cambier S, Sylvester RJ, Collette L, et al. EORTC Nomograms and Risk Groups for 3. Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin. Eur Urol 2016;69(1):60-9.
- 4. Sievert KD, Amend B, Nagele U, et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 2009;27(3):295-300.
- 5. Schmidt S, Francés A, Garin JAL, et al. Quality of life in patients with non-muscle-invasive bladder cancer: One-year results of a multicentre prospective cohort study. Urol Oncol 2015;33(1):19.e7-19.e15.
- Ligibel J. Lifestyle factors in cancer survivorship. J Clin Oncol 2012;30(30):3697-704. 6.
- 7. Mehra K, Berkowitz A, Sanft T. Diet, Physical Activity, and Body Weight in Cancer Survivorship. Med Clin North Am. 2017;101(6):1151-65.
- van Osch FH, Jochems SH, van Schooten F-J, et al. Quantified relations between 8. exposure to tobacco smoking and bladder cancer risk: a meta-analysis of 89 observational studies. Int J Epidemiol 2016;45(3):857-70.
- 9. Cumberbatch MGK, Jubber I, Black PC, et al. Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018. Eur Urol 2018;74(6):784-95.
 - 10. Sun J-W, Zhao L-G, Yang Y, et al. Obesity and risk of bladder cancer: a dose-response meta-analysis of 15 cohort studies. PloS one 2015;10(3):e0119313.
 - 11. Keimling M, Behrens G, Schmid D, et al. The association between physical activity and bladder cancer: systematic review and meta-analysis. Br J Cancer 2014;110(7):1862-70.
- 12. World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project Expert Report 2018: Diet, nutrition, physical activity and bladder cancer. 2018, https://www.wcrf.org/dietandcancer
- 13. Crivelli JJ, Xylinas E, Kluth LA, et al. Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature. Eur Urol 2014;65(4):742-54.
- 14. Hou L, Hong X, Dai M, et al. Association of smoking status with prognosis in bladder cancer: A meta-analysis. Oncotarget 2017;8(1):1278-89.
- 15. Westhoff E, Witjes JA, Fleshner NE, et al. Body Mass Index, Diet-Related Factors, and Bladder Cancer Prognosis: A Systematic Review and Meta-Analysis. Bladder *Cancer* 2018;4(1):91-112.

1 2			
3 4 5 6	401 402 403 404	16.	Kluth LA, Xylinas E, Crivelli JJ, et al. Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder. <i>J Urol</i> 2013;190(2):480-6.
7 8 9	405 406 407	17.	Wyszynski A, Tanyos SA, Rees JR, et al. Body mass and smoking are modifiable risk factors for recurrent bladder cancer. <i>Cancer</i> 2014;120(3):408-14.
10 11 12 13	407 408 409 410 411	18.	Xu T, Zhu Z, Wang X, et al. Impact of body mass on recurrence and progression in Chinese patients with Ta, T1 urothelial bladder cancer. <i>Int Urol Nephrol</i> 2015;47(7):1135-41.
14 15 16	412 413 414	19.	van der Heijden AG, Witjes JA. Recurrence, progression, and follow-up in non- muscle-invasive bladder cancer. <i>Eur Urol Suppl</i> 2009;8(7):556-62.
17 18 19 20	415 416	20.	Sjödahl G, Lauss M, Lövgren K, et al. A molecular taxonomy for urothelial carcinoma. <i>Clin Cancer Res</i> 2012;18:3377-86.
20 21 22 23	417 418 419	21.	Patschan O, Sjödahl G, Chebil G, et al. A molecular pathologic framework for risk stratification of stage T1 urothelial carcinoma. <i>Eur Urol</i> 2015;68(5):824-32.
24 25 26 27	420 421 422 423 424	22.	Jung A, Nielsen ME, Crandell JL, et al. Quality of Life in Non-Muscle-Invasive Bladder Cancer Survivors: A Systematic Review. <i>Cancer Nurs</i> Published Online First: 1 June 2018. doi:10.1097/NCC.000000000000606.
28 29 30	425 426	23.	Mohamed N, Gilbert F, Lee C, et al. Pursuing Quality in the application of bladder Cancer quality of Life Research. <i>Bladder Cancer</i> 2016;2(2):139-49.
31 32 33 34	427 428 429 430	24.	Gopalakrishna A, Longo TA, Fantony JJ, et al. Lifestyle factors and health-related quality of life in bladder cancer survivors: a systematic review. <i>J Cancer Surviv</i> 2016;10(5):874-82.
35 36 37 38 39 40 41	431 432 433 434 435 436 436 437	25.	van de Poll-Franse LV, Horevoorts N, van Eenbergen M, et al. The Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. <i>Eur J Cancer</i> 2011;47(14):2188-94.
42 43 44 45	438 439 440 441	26.	Wendel-Vos GW, Schuit AJ, Saris WH, et al. Reproducibility and relative validity of the short questionnaire to assess health-enhancing physical activity. <i>J Clin Epidemiol</i> 2003;56(12):1163-9.
46 47 48 49	442 443 444	27.	de Hollander EL, Zwart L, de Vries SI, et al. The SQUASH was a more valid tool than the OBiN for categorizing adults according to the Dutch physical activity and the combined guideline. <i>J Clin Epidemiol</i> 2012;65(1):73-81.
50 51 52 53	445 446 447 448	28.	Wagenmakers R, van den Akker-Scheek I, Groothoff JW, et al. Reliability and validity of the short questionnaire to assess health-enhancing physical activity (SQUASH) in patients after total hip arthroplasty. <i>BMC Musculoskelet Disord</i> 2008;9(1):141.
54 55 56 57	449 450 451 452	29.	Siebelink E, Geelen A, de Vries JH. Self-reported energy intake by FFQ compared with actual energy intake to maintain body weight in 516 adults. <i>Br J Nutr</i> 2011;106(2):274-81.
58 59 60	453 454 455	30.	NEVO-tabel (2011) Dutch Food Composition Database. Den Haag: RIVM/Voedingscentrum.

- 31. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85(5):365-76.
- 32. Blazeby JM, Hall E, Aaronson NK, et al. Validation and reliability testing of the EORTC QLQ-NMIBC24 questionnaire module to assess patient-reported outcomes in non-muscle-invasive bladder cancer. Eur Urol 2014;66(6):1148-56.
- 33. Chandrasekar T, Erlich A, Zlotta AR. Molecular Characterization of Bladder Cancer. Curr Urol Rep 2018;19(12):107.
- 34. Babjuk M, Böhle A, Burger M, et al. EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol 2017;71(3):447-61.
- 35. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49(3):466-77.
- 36. Dupont WD, Plummer WD. Power and sample size calculations: a review and computer program. Control Clin Trials 1990;11(2):116-28.
- 37. Dupont WD, Plummer WD. PS: Power and Sample Size Calculation. http://biostat.mc.vanderbilt.edu/wiki/Main/PowerSampleSize. Accessed 16 January 2019.
- Faul F, Erdfelder E, Buchner A, et al. Statistical power analyses using G* Power 3.1: 38. Tests for correlation and regression analyses. Behav Res Methods 2009;41(4):1149-60.
- Faul F, Erdfelder E, Buchner A, et al. G*Power: Statistical Power Analyses for 39. Windows and Mac. http://www.gpower.hhu.de. Accessed 16 January 2019.

1		
2 3	491	FIGURE LEGENDS
4	-51	
5 6	492	Figure 1 Timeline and study design of the UroLife study.
7		
8		
9 10		
11		
12 13		
14		
15 16		
17		
18 10		
19 20		
21		
22 23		
24		
25 26		
27		
28 29		
30		
31 32		
33		
34 35		
36		
37		
38 39		
40		
41 42		
43		
44 45		
46		
47 48		
49		
50 51		
52		
53 54		
55		
56 57		
58		
59 60		
00		

Page 20 of 20






Figure 1 Timeline and study design of the UroLife study.

BMJ Open

The UroLife study: Protocol for a Dutch prospective cohort on lifestyle habits in relation to non-muscle-invasive bladder cancer prognosis and health-related quality of life

	1
Journal:	BMJ Open
Manuscript ID	bmjopen-2019-030396.R2
Article Type:	Protocol
Date Submitted by the Author:	18-Sep-2019
Complete List of Authors:	de Goeij, Liesbeth; Radboudumc, Department for Health Evidence Westhoff, Ellen; Radboudumc, Department for Health Evidence Witjes, JA; Radboudumc, Department of Urology Aben, Katja; Netherlands Comprehensive Cancer Organisation; Radboudumc, Department for Health Evidence Kampman, Ellen; Wageningen University Kiemeney, Lambertus; Radboudumc, Department for Health Evidence Vrieling, Alina; Radboudumc, Department for Health Evidence
Primary Subject Heading :	Urology
Secondary Subject Heading:	Epidemiology
Keywords:	Urological tumours < ONCOLOGY, EPIDEMIOLOGY, NUTRITION & DIETETICS



2		
3 4	1	The UroLife study: Protocol for a Dutch prospective cohort on lifestyle habits in
5 6	2	relation to non-muscle-invasive bladder cancer prognosis and health-related quality of
7 8	3	life
9 10	4	
11 12	5	Liesbeth de Goeij ^a , Ellen Westhoff ^a , J. Alfred Witjes ^b , Katja K.H. Aben ^{a,c} , Ellen Kampman ^d ,
13 14	6	Lambertus A.L.M. Kiemeney ^{a,b} , Alina Vrieling ^{a*}
15 16	7	
17 18 10	8	^a Radboud university medical center, Radboud Institute for Health Sciences, Nijmegen, The
19 20 21 22	9	Netherlands
22 23 24	10	^b Radboud University Nijmegen Medical Center, Department of Urology, Nijmegen, The
25 26	11	Netherlands
27 28 29	12	° Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands
30 31 32	13	^d Wageningen University, Division of Human Nutrition and Health, Wageningen, The
33 34	14	Netherlands
35 36 37	15	
38 39	16	*Corresponding author: Dr. Alina Vrieling, Radboud university medical center, Department
40 41 42	17	for Health Evidence (Mailbox 133), P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.
43 44	18	Tel: +31 24 3616944, Fax: +31 24 3613505, e-mail: Alina.Vrieling@radboudumc.nl
45 46 47	19	
48 49	20	Word count: 3040
50 51 52 53 54 55 56 57 58 59 60	21	

22 ABSTRACT

23 Introduction:

Patients with non-muscle-invasive bladder cancer (NMIBC) have a good survival but are at high risk for tumour recurrence and disease progression. It is important to identify lifestyle habits that may reduce the risk of recurrence and progression and improve health-related quality of life (HRQOL). This paper describes the rationale and design of the UroLife study. The main aim of this study is to evaluate whether lifestyle habits are related to prognosis and HRQOL in patients with NMIBC.

30 Methods and analysis:

The UroLife study is a multi-centre prospective cohort study among more than 1,100 newly diagnosed patients with NMIBC recruited from 22 hospitals in the Netherlands. At six weeks and three, 15, and 51 months after diagnosis, participants fill out a general questionnaire, and questionnaires about their lifestyle habits and HRQOL. At three, 15, and 51 months after diagnosis, information about fluid intake and micturition is collected with a four-day diary. At three and 15 months after diagnosis, patients donate blood samples for DNA extraction and (dietary) biomarker analysis. Tumour samples are collected from all patients with T1 disease to assess molecular subtypes. Information about disease characteristics and therapy for the primary tumour and subsequent recurrences is collected from the medical records by the Netherlands Cancer Registry. Statistical analyses will be adjusted for age, gender, tumour characteristics and other known confounders.

42 Ethics and dissemination:

47
43 The study protocol has been approved by the Committee for Human Research region
49
44 Arnhem-Nijmegen (CMO 2013-494). Patients who agree to participate in the study provide
45 written informed consent. The findings from our study will be disseminated through peer46 reviewed scientific journals and presentations at (inter)national scientific meetings. Patients
47 will be informed about the progress and results of this study through biannual newsletters
48 and through the website of the study and of the bladder cancer patient association.

1 2		
2 3 4	50	Keywords: bladder cancer, diet, lifestyle, biomarkers, recurrence, prognosis, quality of life,
5 6 7	51	cohort, study protocol
8 9	52	
10 11 12	53	STRENGTHS AND LIMITATIONS OF THIS STUDY
12 13 14	54	Large multicenter prospective cohort study of NMIBC patients recruited shortly after
15 16	55	diagnosis
17 18	56	• Extensive dietary, lifestyle, medical, and HRQOL data at multiple time points after
19 20	57	diagnosis
21 22	58	• Availability of blood samples at 3 and 15 months after diagnosis, and formalin-fixed,
23 24 25	59	paraffin-embedded tumour tissue
25 26 27	60	Limited power for subgroup analyses
28 29	61	 Loss to follow-up potentially influencing validity of results
30 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 950 51 52 53 54 55 56 57 58 59 60	62	

63 INTRODUCTION

Urinary bladder cancer is the sixth most common cancer in the male population worldwide and tenth if considering both genders.[1] Approximately 75% of patients is diagnosed with non-muscle-invasive (NMIBC, stages Ta, T1, and Tis) and 25% with muscle-invasive (MIBC, stages T2, T3, and T4) bladder cancer.[2] Patients with NMIBC have a good survival but are at high risk for tumour recurrence and disease progression.[3] They are therefore subjected to frequent follow-up by cystoscopy and treatment. This makes bladder cancer the most expensive cancer in terms of health care expenditures per patient per year.[4] The high recurrence rate may also impact health-related guality of life (HRQOL).[5] Lifestyle factors have been linked to the prognosis and quality of life in patients with several cancer types [6, 7] but evidence in patients with NMIBC is scarce. If we can identify lifestyle habits that are related to the risk of recurrence and progression and HRQOL in patients with NMIBC, optimal interventions can be developed to improve their prognosis and HRQOL.

The primary risk factor for bladder cancer is smoking, which accounts for 43% of bladder cancer cases in men and 26% in women in Europe.[8] Other important risk factors for bladder cancer are occupational exposures to carcinogens like aromatic amines and polycyclic aromatic hydrocarbons (PAHs), family history, and specific low penetrance germline genetic variants.[9] Recent meta-analyses suggest that excess body weight [10] and physical inactivity [11] may also increase bladder cancer risk. The World Cancer Research Fund/American Institute for Cancer Research (The WCRF/AICR) report found probable evidence that arsenic in drinking water increases the risk of bladder, and limited suggestive evidence that higher consumption of fruit and vegetables and of tea decreases the risk of bladder cancer.[12] For other dietary and lifestyle factors, this report concluded that data were of too low quality, inconsistent, or the number of studies were insufficient to draw conclusions.[12]

Available evidence about the role of lifestyle habits on prognosis in patients with NMIBC is
 restricted to smoking [13, 14] and excess body weight.[15] A systematic review [13] and
 recent meta-analysis of 10 studies including a total of 6,307 patients with NMIBC [14] found

Page 5 of 20

BMJ Open

that current and former smokers at diagnosis had an approximately 25% increased risk of recurrence compared to never smokers. Our recent meta-analysis [15] of three studies [16-18] showed that overweight and obesity compared to normal weight at diagnosis were associated with increased risk of recurrence but not progression in patients with NMIBC, although power for progression was limited.[15] Smoking cessation and weight loss after diagnosis in relation to clinical outcomes has hardly been investigated. Evidence for other lifestyle habits, such as fluid intake and micturition, physical activity, and fruit and vegetable consumption, is very limited or not available.[15] Also, most studies on lifestyle and NMIBC prognosis included a heterogeneous study population with different tumour stages and grades of bladder cancer. However, NMIBC prognosis is clearly different for these subgroups [19] and may also differ by molecular subtype. [20, 21] Whether associations of lifestyle habits with NMIBC prognosis are mediated and/or modified by tumour stage and by molecular subtype has not yet been investigated.

104 Despite the high frequency of surveillance and repeated treatments, relatively little is known
 about the HRQOL of patients with NMIBC,[22] and research with validated bladder cancer specific instruments is needed.[23] A systematic review of five studies on lifestyle and
 HRQOL in bladder cancer patients found some evidence for a positive association between
 physical activity and HRQOL, but insufficient evidence to draw any conclusions for
 consumption of fruit and vegetables or smoking cessation.[24]

The aim of our study is to evaluate the association of pre- and post-diagnosis lifestyle habits (and habit changes) with risk of recurrence and progression and HRQOL. Also, we want to explore whether this association is mediated and/or modified by tumour stage and molecular subtype.

115 METHODS AND ANALYSIS

The UroLife study (Urothelial cell cancer: Lifestyle, prognosis, and quality of Life) is a prospective cohort study including patients with newly diagnosed NMIBC. The study has been designed to evaluate the association of lifestyle habits with risk of recurrence and progression and HRQOL. Patients are recruited in 22 hospitals in the East, South, and Central part of the Netherlands. Before the start of the study, permission was asked from all urologists of the participating hospitals to select and invite eligible patients from the Netherlands Cancer Registry (NCR), held by the Netherlands Comprehensive Cancer Organisation (IKNL). Once every 1 to 2 weeks, new patients are identified through IKNL using notification lists of the nationwide network and registry of histo- and cytopathology in the Netherlands (PALGA foundation). Approximately 4 weeks after diagnosis, patients are invited on behalf of their urologist to participate in this study. Patients who agree to participate provide a written informed consent.

129 Patient population

Eligible participants are Dutch speaking patients between 18 and 80 years old who are newly diagnosed with a histologically confirmed primary stage Ta, T1, and Tis NMIBC tumour and underwent a transurethral resection. Patients with a previous diagnosis of cancer in the past five years and those with a lymph node metastasis or distant metastasis are not eligible.

- ⁴⁵ 135 Patient and public involvement
 ⁴⁶
- ⁴⁷ 136 Patients were not involved in the design, recruitment and conduct of the study.
- 51138Data collection and management
- ⁵³ ₅₄ 139 *Questionnaires*

Participants are asked to complete self-administered web-based or paper-and-pencil-based
questionnaires at six weeks (T6wk), three months (T3mo), 15 months (T15mo), and 51
months (T51mo) after diagnosis (Figure 1, Table 1). Web-based questionnaires are collected

BMJ Open

using the data collection tool of the Patient Reported Outcomes Following Initial treatment
and Long term Evaluation of Survivorship (PROFILES) registry.[25] Follow-up telephone
calls are made to non-responding participants and to respondents whose questionnaires
have missing items.

The baseline questionnaire contains questions on demographics (age, sex, ethnicity, education, living situation, occupation, marital status) and (family) history of cancer. All questionnaires collect information about height, body weight, amount and frequency of alcohol consumption during week- and weekend days, smoking habits, comorbidities and the use of medication. Information on smoking habits is collected in detail, including age or date of starting and stopping smoking, number of cigarettes smoked per day, duration of smoking, and passive exposure to smoking. Information about habitual physical activity is collected by using the previously validated Short QUestionnaire to ASsess Health-enhancing physical activity (SQUASH),[26] which is fairly reliable and valid in an adult population.[26-28] The SQUASH questionnaire assesses the average time, i.e. number of days per week and hours and minutes per day, spent in commuting activities, leisure time activities, household activities, and activities at work in a normal week in the past month. At T3mo, T15mo, and T51mo, patients are also asked to measure and report their waist and hip circumference.

1 161

Habitual dietary intake is collected using a 163-item validated and reproducible self-administered food frequency questionnaire that was developed by Wageningen University.[29] The questionnaire contains questions about the frequency of consumption of food products and the portion size during the previous year (T6wk) or the previous months (T3mo, T15mo, and T51mo). Frequency and portion size of consumed food products are multiplied to obtain their intake in grams per day. Nutrient intake is calculated using the Dutch Food Composition Database (NEVO 2011).[30] Information about fluid intake and micturition is collected with a four-day diary at T3mo, T15mo en T51mo.

BMJ Open

HRQOL is assessed at all four time points with the validated European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 [31] and a 24-item module for patients with NMIBC, i.e. the EORTC QLQ-NMIBC24.[32] The EORTC QLQ-C30 contains five function scales (physical, role, cognitive, emotional and social functioning), three symptom scales (fatigue, nausea, pain and vomiting) and six single items (dyspnea, insomnia, loss of appetite, constipation, diarrhea, and financial impact), all scored from 1 (not at all) to 4 (very much)) and a global health status scale with ranges from 1 (very poor) to 7 (excellent). The EORTC QLQ-NMIBC24 contains six scales (urinary symptoms, malaise, future worries, bloating and flatulence, sexual function, and male sexual function) and five single items (intravesical treatment issues, sexual intimacy, risk of contaminating partner, sexual enjoyment, female sexual problems) scored from 1 (not at all) to 4 (very much). All scores will be linearly transformed to a 0 to 100 scale.

> Furthermore, at T3mo patients are asked to report whether they are aware of possible risk factors for (bladder) cancer, received lifestyle advice from their physician, and what their attitudes are towards physicians giving lifestyle advice.

Page 9 of 20		BMJ Open	bmjopen-2019-030396 c			
			en-20			
1 2 187	Table 1 Overview of data collection in Uro	Life at the four time points)19-(
2 187 3		Included topics	OT6wk	T3mo	T15mo	T51mo
4	Questionnaires			151110	1151110	131110
5	Sociodemographic data	Date of birth, gender, living situation, marital status, country of birth of participant, father,	Sx Sx			
6	Sociouemographic data	mother, race, highest level of education, working history, occupational exposure	n 16			
7		mother, race, highest level of education, working history, occupational exposure	0 0			
8	Anthropometry	Height at diagnosis, weight two years before diagnosis, weight at age 18 years, average	October 2019.			
9	, intil openietry	weight during adult life	ber			
10		Current body weight, waist and hip circumference	NX	Х	х	х
11			9			
12	Lifestyle	Current and past smoking behaviour, environmental smoke exposure		Х	Х	Х
13		Short Questionnaire to Assess Health-enhancing physical activity [26]	≦x	Х	Х	Х
14		Frequency and amount of alcohol consumption during week and weekend days	<u>o</u> x	Х	Х	Х
15		Changes in eating habits and reasons for/type of changes	ade	Х	Х	Х
16			ă f			
17	Medical history	Previously diagnosed with cancer, family history of cancer	дx			
18		Comorbidities, medication use, dietary supplement use	ĘX	Х	Х	Х
19			tp:/			
20	Questions for females	Menstruation, menopause, use of contraceptives, use of hormone replacement therapy	gx	Х	Х	Х
21		Pregnancy	, дх			
22			ben			
23	Diet	163- item Food Frequency Questionnaire	<u>b</u> X	Х	Х	Х
24			-j. .0			
25	HRQOL	EORTC QLQ-C30 [31] and EORTC QLQ-NMIBC24 [32]	Bx	Х	Х	Х
26			or			
27	Awareness risk factors and lifestyle advice	Awareness of cancer risk factors, received lifestyle advice, attitudes towards lifestyle advice	Ā	Х		
28	Four-day diary		Bownlöaded fröm http://bmjöpen.bmj.com/ on April 20,			
29		Frequency micturition, amount and type of fluid intake	20,	х	х	Х
30	Blood					
31	2.002	EDTA whole blood for DNA isolation	24	х		
32		EDTA plasma, heparin plasma	2024 by gu	X	х	
33	T ¹					
34	Tissue	Formalis fixed poweffic and added tions of the asimomy type out	est.			
35		Formalin-fixed paraffin-embedded tissue of the primary tumour	ਧੂ			
36	Clinical data		ote			
37		Disease characteristics, therapy	Sex 2	х	Х	Х
38		Recurrence and progression	est. Protected by		Х	Х
39 40						
40 41			copyright			
41 42		9	righ			
42 43			.t.			
43 44		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml				
45						
- -						

Blood samples

Non-fasting blood samples are collected at T3mo and T15mo. At T3mo, 10 ml EDTA whole blood (for DNA isolation), 10 ml EDTA plasma and 10 ml heparin plasma is collected. At T15mo, 10 ml EDTA plasma and 10 ml heparin plasma is collected. Heparin plasma tubes are wrapped in aluminum foil to protect them from light. All blood samples are collected, processed and stored at -80°C locally in the participating hospitals according to a standard protocol before transportation on dry ice to the Radboud Biobank. The blood samples are stored in the Radboud Biobank at -80°C for future analyses of genetic and other biomarkers. Analysis of heparin plasma levels of nine biomarkers of fruit and vegetable consumption is planned. Concentration of six carotenoids (i.e. alpha-carotene, beta-carotene, beta-cryptoxanthin, lutein, lycopene and zeaxanthin), alpha-tocopherol, beta- and gamma-tocopherol and retinol were measured by HPLC (Thermo Scientific Accela LC system; Thermo Fisher Scientific) and analyzed by using ChromQuest 5.0, Version 3.2.1 software (Thermo Fisher Scientific).

Tumour samples

From patients diagnosed with T1 NMIBC, tumour specimens will be collected in two batches in 2019 and 2021. Tumour blocks will be identified by using the PALGA foundation and retrieved using the Dutch National Tissuebank Portal (DNTP) from the local pathology laboratories. Pathology review will be performed and tissue microarrays will be constructed. Molecular subtypes will be assessed by immunohistochemistry in 2021. As the development of a molecular classification system for NMIBC is still in progress and no consensus system is available yet, [33] we will use the most suitable evidence-based subtyping method that will then be available.

Clinical data

For all patients with NMIBC, information about disease characteristics and therapy for the initial tumour is collected from the medical records by data managers of the Netherlands

Page 11 of 20

BMJ Open

Cancer Registry. Information about tumour characteristics includes incidence date, clinical (cTNM) and post-surgical (pTNM) stage,[34] tumour grade, concomitant carcinoma in situ, multifocality, number of tumours and histology. With respect to therapy, information is collected on type of cystoscopy (white or blue light) and on transurethral resection (TUR), i.e. date of TUR, presence of detrusor in the surgical specimen, and presence of lymphovascular invasion. Furthermore, data on local treatment (e.g., intravesical chemotherapy, BCG) with start and stop dates and, if applicable, on cystectomy (e.g., date, type) are collected.

Data on clinical outcomes, i.e. recurrence and progression, with dates of diagnosis, tumour characteristics, and therapy is also collected from the medical records by data managers of the Netherlands Cancer Registry. Information on vital status is collected by linkage with the Personal Records Database. All patients will be followed for at least 5 years.

Power considerations & Data analysis

Risk of recurrence (or progression) will be evaluated as time to first recurrence (or progression). The association of pre- and post-diagnostic lifestyle factors, as well as changes in lifestyle factors, with risk of recurrence and progression will be evaluated by estimating hazard ratios and 95% confidence intervals using Cox proportional hazards regression analyses. All analyses will be adjusted for age, gender, tumour characteristics, and other known confounders. Analytical techniques for longitudinal data and multiple outcomes will also be explored and applied. Our power calculation is based on 1,100 patients who will be followed for five years. For comparing the highest (n=275) vs. lowest guartile (n=275) of a lifestyle factor (or vice versa), this study will be sufficiently powered (two-sided alpha=0.05, power 80%) to detect a hazard ratio of \geq 1.5 or \geq 1.3 (or \leq 0.7 or \leq 0.8) when assuming a five-year recurrence risk of 31% or 78%,[35] respectively.[36, 37] With an assumed loss to followup of 25% after five years, detectable hazard ratios will increase to \geq 1.6 or \geq 1.4 (or \leq 0.6 or \leq 0.7), respectively. Lower hazard ratios can be detected when lifestyle factors are modeled continuously.

BMJ Open

The association of lifestyle factors with HRQOL will be evaluated using longitudinal mixed model analyses, taking into account the within-subject variation in lifestyle and HRQOL over time and the between-subject variation. All analyses will be adjusted for age, gender, tumour characteristics, and other known confounders. Since we expect that the between-subject variation in lifestyle and HRQOL will be much larger than the within-subject variation, most information will come from the association observed between subjects and not from the association observed within subjects over time, Therefore, our power calculation is based on a cross-sectional correlation at one time point. With 825 patients (assuming a loss to followup of 25%) and using 10 predictor variables, we have 80% power to detect a small correlation (Cohen's f² of 0.02).[38, 39] Power will be higher when using repeated measurements over time, especially when there is within-subject variation of lifestyle factors and HRQOL over time.

° 257

258 Cohort status

Medical ethical approval was obtained on 17 January 2014. Patient recruitment started in May 2014. Between 8 May 2014 and 25 April 2017, 2,133 patients with NMIBC initially diagnosed with Ta, T1, or Tis tumours have been identified and invited to participate in UroLife. Of these invited patients, 1,193 patients agreed to participate and 77 dropped out before filling out the first questionnaires (response rate 52%). Since May 2017, recruitment of patients with T1 (but not Ta or Tis) tumours has continued and is still ongoing. We aim to recruit a total of at least 700 patients with T1 bladder cancer, and the projected date of recruitment completion is April 2021.

268 DISCUSSION

The UroLife study is one of the largest multicenter prospective cohort studies on lifestyle and NMIBC outcomes worldwide. UroLife will provide new and comprehensive insights into whether lifestyle habits (or habit changes) are related to NMIBC outcomes and HRQOL, and whether these relations differ by tumour stage and molecular subtype. Unique features of Page 13 of 20

 BMJ Open

UroLife are the recruitment of patients shortly after diagnosis, collection of extensive dietary, lifestyle, medical, and HRQOL data at multiple time points after diagnosis, collection of blood (for DNA and biomarker analysis), and the availability of tumour tissue samples (for molecular classification).

As in many prospective cohort studies, non-participation may limit the generalisability of our findings. In addition, loss to follow-up may limit the validity of our findings. Information bias due to reliance on recall and self-report, or due to missing data, may be another potential limitation. Although our study is large, we intend to combine our dataset in the future with other similar prospective studies in NMIBC to increase statistical power for subgroup analyses.

If the results of this study show that lifestyle factors are associated with clinical outcomes in NMIBC patients and these results are confirmed by other prospective studies or randomised trials, lifestyle recommendations and lifestyle interventions can be developed. Patients diagnosed with NMIBC could then be advised by their physician about their lifestyle and/or referred to a lifestyle intervention (e.g. smoking cessation program, exercise program). Thus, our ultimate aim is to provide personalized evidence-based lifestyle advice to patients with NMIBC, also according to tumour stage and molecular subtype, to enable them to have an influence on their clinical outcome.

ETHICS AND DISSEMINATION

The study protocol has been approved by the Committee for Human Research region Arnhem-Nijmegen (CMO 2013-494). Patients who agree to participate in the study provide written informed consent. The findings from our cohort study will be disseminated through peer-reviewed scientific journals, and presentations at (inter)national scientific meetings. Patients will be informed about the progress and results of this study through biannual newsletters and through the website of the study (https://www.radboudumc.nl/trials/urolife) and of the bladder cancer patient association (https://www.blaasofnierkanker.nl/). Also, presentations will be given at contact days of the bladder cancer patient association.

2 3 4	301	DECLARATIONS
5 6 7 8 9 10	302	
	303	Authors' contributions
	304	AV, LALMK, AJW, EK, and KKHA contributed to the conception and design of the study. AV
11 12	305	provides overall study management and coordinates the project. EW has contributed and
13 14	306	LdG contributes to data collection. LdG, EW and AV drafted the manuscript. All authors have
15 16	307	critically read and revised the manuscript. All authors approved the final version of the
 17 18 19 20 21 22 23 24 25 	308	manuscript.
	309	
	310	Funding
	311	This work was supported by Alpe d'HuZes/Dutch Cancer Society (KUN 2013-5926) and
26 27	312	Dutch Cancer Society (Project no. 11179). Sponsors were not involved in the study design
28 29 30 31 32 33 34 35 36 37 38 39 40 41 42	313	nor will they be in the collection, analysis, and interpretation of data, or in the publications
	314	that will result from this study.
	315	
	316	Competing interests
	317	The authors declare that they have no competing interests.
	318	
	319	Availability of data and material
43 44	320	Data and material are not yet available since enrollment to the study is still ongoing and data
45 46	321	collection has not been completed yet. After completion of data collection, data will be made
47 48	322	available by the corresponding author upon reasonable request.
49 50	323	
51 52	324	Acknowledgements
53 54 55	325	We are grateful to all the patients who participate in this study and we would like to thank the
56 57	326	following hospitals for their involvement in recruitment for the UroLife study: Amphia
58 59	327	Ziekenhuis, Breda/Oosterhout (Drs. D.K.E. van der Schoot); Ziekenhuis Bernhoven, Uden
60	328	(Drs. A.Q.H.J. Niemer); Canisius-Wilhelmina Ziekenhuis, Nijmegen (Dr. D.M. Somford);

Page 15 of 20

BMJ Open

3 4	329	Catharina Ziekenhuis, Eindhoven (Dr. E.L. Koldewijn); Deventer Ziekenhuis, Deventer (Drs.
5 6	330	P.L.M. van den Tillaar); Elkerliek Ziekenhuis, Helmond (Drs. E.W. Stapper †, Drs. P.J. van
7 8	331	Hest); Gelre Ziekenhuizen, Apeldoorn/Zutphen (Drs. D.M. Bochove-Overgaauw); Isala
9 10	332	Klinieken, Zwolle (Dr. E. te Slaa); Jeroen Bosch Ziekenhuis, 's-Hertogenbosch (Dr. J.R.
11 12	333	Oddens; Dr. S. van der Meer); Meander Medisch Centrum, Amersfoort (Drs. F.S. van Rey);
13 14	334	Medisch Spectrum Twente, Enschede (Dr. M. Asselman); Maxima Medisch Centrum,
15 16	335	Veldhoven/Eindhoven (Dr. L.M.C.L. Fossion); Maasziekenhuis Pantein, Boxmeer (Drs. E.
 17 18 19 20 21 22 23 24 25 	336	van Boven); Radboudumc, Nijmegen (Prof. Dr. J.A. Witjes); Rijnstate,
	337	Arnhem/Velp/Zevenaar (Drs. C.J. Wijburg); Slingeland Ziekenhuis, Doetinchem (Drs. A.D.H.
	338	Geboers); St. Anna Ziekenhuis, Geldrop (Drs. A. Sonneveld); Elisabeth-TweeSteden
	339	Ziekenhuis, Tilburg/Waalwijk (Dr. P.J.M. Kil); St. Jansdal Ziekenhuis, Harderwijk (Drs. W.J.
26 27	340	Kniestedt); VieCuri, Venlo (Drs. G. Yurdakul, Dr. A.H.P. Meier); Ziekenhuis Gelderse Vallei,
28 29	341	Ede (Drs. M.D.H. Kortleve); Ziekenhuisgroep Twente, Almelo/Hengelo (Dr. E.B. Cornel). In
30 31	342	addition, we thank Ms. Monique Eijgenberger for her assistance in data collection. We also
32 33	343	thank the data managers and research assistants of the Netherlands Cancer Registry held
34 35	344	by the Netherlands Comprehensive Cancer Organisation (IKNL) for inviting patients and
36 37 38 39 40	345	collecting the clinical data.
	346	

REFERENCES

- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN 1. estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394-424.
- Babjuk M, Böhle A, Burger M, et al. EAU guidelines on non-muscle-invasive 2. urothelial carcinoma of the bladder: update 2016. Eur Urol 2017;71(3):447-61.
- Cambier S, Sylvester RJ, Collette L, et al. EORTC Nomograms and Risk Groups for 3. Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin. Eur Urol 2016;69(1):60-9.
- 4. Sievert KD, Amend B, Nagele U, et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 2009;27(3):295-300.
- 5. Schmidt S, Francés A, Garin JAL, et al. Quality of life in patients with non-muscle-invasive bladder cancer: One-year results of a multicentre prospective cohort study. Urol Oncol 2015;33(1):19.e7-19.e15.
- Ligibel J. Lifestyle factors in cancer survivorship. J Clin Oncol 2012;30(30):3697-704. 6.
- 7. Mehra K, Berkowitz A, Sanft T. Diet, Physical Activity, and Body Weight in Cancer Survivorship. Med Clin North Am. 2017;101(6):1151-65.
- van Osch FH, Jochems SH, van Schooten F-J, et al. Quantified relations between 8. exposure to tobacco smoking and bladder cancer risk: a meta-analysis of 89 observational studies. Int J Epidemiol 2016;45(3):857-70.
- 9. Cumberbatch MGK, Jubber I, Black PC, et al. Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018. Eur Urol 2018;74(6):784-95.
 - 10. Sun J-W, Zhao L-G, Yang Y, et al. Obesity and risk of bladder cancer: a dose-response meta-analysis of 15 cohort studies. PloS one 2015;10(3):e0119313.
 - 11. Keimling M, Behrens G, Schmid D, et al. The association between physical activity and bladder cancer: systematic review and meta-analysis. Br J Cancer 2014;110(7):1862-70.
- 12. World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project Expert Report 2018: Diet, nutrition, physical activity and bladder cancer. 2018, https://www.wcrf.org/dietandcancer
- 13. Crivelli JJ, Xylinas E, Kluth LA, et al. Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature. Eur Urol 2014;65(4):742-54.
- 14. Hou L, Hong X, Dai M, et al. Association of smoking status with prognosis in bladder cancer: A meta-analysis. Oncotarget 2017;8(1):1278-89.
- 15. Westhoff E, Witjes JA, Fleshner NE, et al. Body Mass Index, Diet-Related Factors, and Bladder Cancer Prognosis: A Systematic Review and Meta-Analysis. Bladder *Cancer* 2018;4(1):91-112.


1 2			
3 4 5 6	401 402 403 404	16.	Kluth LA, Xylinas E, Crivelli JJ, et al. Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder. <i>J Urol</i> 2013;190(2):480-6.
7 8 9	405 406 407	17.	Wyszynski A, Tanyos SA, Rees JR, et al. Body mass and smoking are modifiable risk factors for recurrent bladder cancer. <i>Cancer</i> 2014;120(3):408-14.
10 11 12 13	407 408 409 410 411	18.	Xu T, Zhu Z, Wang X, et al. Impact of body mass on recurrence and progression in Chinese patients with Ta, T1 urothelial bladder cancer. <i>Int Urol Nephrol</i> 2015;47(7):1135-41.
14 15 16	412 413 414	19.	van der Heijden AG, Witjes JA. Recurrence, progression, and follow-up in non- muscle-invasive bladder cancer. <i>Eur Urol Suppl</i> 2009;8(7):556-62.
17 18 19 20	415 416	20.	Sjödahl G, Lauss M, Lövgren K, et al. A molecular taxonomy for urothelial carcinoma. <i>Clin Cancer Res</i> 2012;18:3377-86.
20 21 22 23	417 418 419	21.	Patschan O, Sjödahl G, Chebil G, et al. A molecular pathologic framework for risk stratification of stage T1 urothelial carcinoma. <i>Eur Urol</i> 2015;68(5):824-32.
24 25 26 27	420 421 422 423 424	22.	Jung A, Nielsen ME, Crandell JL, et al. Quality of Life in Non-Muscle-Invasive Bladder Cancer Survivors: A Systematic Review. <i>Cancer Nurs</i> Published Online First: 1 June 2018. doi:10.1097/NCC.0000000000000606.
28 29 30	425 426	23.	Mohamed N, Gilbert F, Lee C, et al. Pursuing Quality in the application of bladder Cancer quality of Life Research. <i>Bladder Cancer</i> 2016;2(2):139-49.
31 32 33 34	427 428 429 430	24.	Gopalakrishna A, Longo TA, Fantony JJ, et al. Lifestyle factors and health-related quality of life in bladder cancer survivors: a systematic review. <i>J Cancer Surviv</i> 2016;10(5):874-82.
35 36 37 38 39 40 41	431 432 433 434 435 436 436 437	25.	van de Poll-Franse LV, Horevoorts N, van Eenbergen M, et al. The Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. <i>Eur J Cancer</i> 2011;47(14):2188-94.
42 43 44 45	438 439 440 441	26.	Wendel-Vos GW, Schuit AJ, Saris WH, et al. Reproducibility and relative validity of the short questionnaire to assess health-enhancing physical activity. <i>J Clin Epidemiol</i> 2003;56(12):1163-9.
46 47 48 49	442 443 444	27.	de Hollander EL, Zwart L, de Vries SI, et al. The SQUASH was a more valid tool than the OBiN for categorizing adults according to the Dutch physical activity and the combined guideline. <i>J Clin Epidemiol</i> 2012;65(1):73-81.
50 51 52 53	445 446 447 448	28.	Wagenmakers R, van den Akker-Scheek I, Groothoff JW, et al. Reliability and validity of the short questionnaire to assess health-enhancing physical activity (SQUASH) in patients after total hip arthroplasty. <i>BMC Musculoskelet Disord</i> 2008;9(1):141.
54 55 56 57	449 450 451 452	29.	Siebelink E, Geelen A, de Vries JH. Self-reported energy intake by FFQ compared with actual energy intake to maintain body weight in 516 adults. <i>Br J Nutr</i> 2011;106(2):274-81.
58 59 60	453 454 455	30.	NEVO-tabel (2011) Dutch Food Composition Database. Den Haag: RIVM/Voedingscentrum.

- 31. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85(5):365-76.
- 32. Blazeby JM, Hall E, Aaronson NK, et al. Validation and reliability testing of the EORTC QLQ-NMIBC24 questionnaire module to assess patient-reported outcomes in non-muscle-invasive bladder cancer. Eur Urol 2014;66(6):1148-56.
- 33. Chandrasekar T, Erlich A, Zlotta AR. Molecular Characterization of Bladder Cancer. Curr Urol Rep 2018;19(12):107.
- 34. Babjuk M, Böhle A, Burger M, et al. EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol 2017;71(3):447-61.
- 35. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49(3):466-77.
- 36. Dupont WD, Plummer WD. Power and sample size calculations: a review and computer program. Control Clin Trials 1990;11(2):116-28.
- 37. Dupont WD, Plummer WD. PS: Power and Sample Size Calculation. http://biostat.mc.vanderbilt.edu/wiki/Main/PowerSampleSize. Accessed 16 January 2019.
- Faul F, Erdfelder E, Buchner A, et al. Statistical power analyses using G* Power 3.1: 38. Tests for correlation and regression analyses. Behav Res Methods 2009;41(4):1149-60.
- Faul F, Erdfelder E, Buchner A, et al. G*Power: Statistical Power Analyses for 39. Windows and Mac. http://www.gpower.hhu.de. Accessed 16 January 2019.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1		
2 3	491	FIGURE LEGENDS
4	-51	
5 6	492	Figure 1 Timeline and study design of the UroLife study.
7		
8		
9 10		
11		
12 13		
14		
15 16		
17		
18 10		
19 20		
21		
22 23		
24		
25 26		
27		
28 29		
30		
31 32		
33		
34 35		
36		
37		
38 39		
40		
41 42		
43		
44 45		
46		
47 48		
49		
50 51		
52		
53 54		
55		
56 57		
58		
59 60		
00		

Page 20 of 20






Figure 1 Timeline and study design of the UroLife study.

BMJ Open: first published as 10.1136/bmjopen-2019-030396 on 16 October 2019. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright.